<SEC-DOCUMENT>0001737287-20-000036.txt : 20200603
<SEC-HEADER>0001737287-20-000036.hdr.sgml : 20200603
<ACCEPTANCE-DATETIME>20200603161412
ACCESSION NUMBER:		0001737287-20-000036
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20200603
DATE AS OF CHANGE:		20200603

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Allogene Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001737287
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				823562771
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-234516
		FILM NUMBER:		20940140

	BUSINESS ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 457-2700

	MAIL ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>allo-20200603x424bprosupp.htm
<DESCRIPTION>424B5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ieed28d9304df4001833e3a91896e00cb_534"></div><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Filed Pursuant to Rule 424(b)(5)</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Registration No.  333-234516</font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CALCULATION OF REGISTRATION FEE</font></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:3.208%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.114%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.932%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.015%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.015%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.716%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:3pt double #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of Each Class of Securities to be Registered</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:3pt double #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount to be Registered</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:3pt double #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proposed Maximum Offering Price per Share</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:3pt double #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proposed Maximum Aggregate Offering Price</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:3pt double #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Registration Fee<br>(2)</font></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock, $0.0001 par value per share</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,457,447 (1)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$47.00</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$632,500,009</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$82,098.50</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</font></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Includes shares of Common Stock that may be purchased by the underwriters pursuant to their option to purchase additional shares of Common Stock.</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</font></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The registration fee is calculated and being paid pursuant to Rule 457(r) under the Securities Act of 1933, as amended, and relates to the Registration Statement on Form S-3ASR (File No. 333-234516) filed by the Registrant on November 5, 2019.</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_1"></div><hr style="page-break-after:always"><div style="height:40.5pt;width:100%;"><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div><div style="text-align:right;"><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Prospectus Supplement </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(To prospectus dated November 5, 2019) </font></div><div style="text-indent:27pt;text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%;">11,702,128 Shares</font></div><div style="text-indent:27pt;text-align:center;"><img alt="image_02.jpg" src="image_02.jpg" style="height:83px;width:305px;"></div><div style="text-indent:27pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%;">Common Stock</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:79.783%;"><tr><td style="width:1.0%;"></td><td style="width:35.137%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.725%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.138%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are offering 11,702,128 shares of our common stock. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#8220;ALLO.&#8221; On June 1, 2020, the last reported sale price of our common stock was $48.94 per share. </font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:79.783%;"><tr><td style="width:1.0%;"></td><td style="width:35.137%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.725%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.138%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investing in our common stock involves a high degree of risk. See </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><a href="#ieed28d9304df4001833e3a91896e00cb_13" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: none;">&#8220;</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_13" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration: underline;">Risk Factors</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><a href="#ieed28d9304df4001833e3a91896e00cb_13" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: none;">&#8221;</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> on page S-5 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement before investing in our common stock. </font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:79.783%;"><tr><td style="width:1.0%;"></td><td style="width:35.137%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.725%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.138%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:70.685%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.037%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.577%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.501%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Per Share</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Public offering price</font></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47.00&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">550,000,016&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Underwriting discount</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7025&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,625,001&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Proceeds, before expenses, to Allogene Therapeutics, Inc. </font></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44.2975&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">518,375,015&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr></table></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:36.574%;"><tr><td style="width:1.0%;"></td><td style="width:21.628%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:74.372%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)&#160;See the section entitled &#8220;Underwriting&#8221; for additional information regarding compensation payable to the underwriters. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have granted the underwriters a 30-day option to purchase up to an additional 1,755,319 shares of our common stock at the price to the public less the underwriting discount. </font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:78.086%;"><tr><td style="width:1.0%;"></td><td style="width:35.944%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.284%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:33.772%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The underwriters expect to deliver the shares against payment in New York, New York on or about June 4, 2020. </font></div><div style="text-indent:27pt;text-align:center;margin-top:10pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Joint Lead Book-Running Managers </font></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.679%;"><tr><td style="width:1.0%;"></td><td style="width:36.548%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:22.677%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:34.775%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:14pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goldman Sachs &#38; Co. LLC</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:14pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jefferies</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:14pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cowen</font></td></tr></table></div><div style="text-indent:27pt;text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Book-Running Manager</font></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.679%;"><tr><td style="width:1.0%;"></td><td style="width:36.548%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:22.677%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:34.775%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:14pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><font style="font-size:14pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:14pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Piper Sandler</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:14pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><font style="font-size:14pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></font></td></tr></table></div><div style="text-indent:27pt;text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Co-Lead Managers</font></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.679%;"><tr><td style="width:1.0%;"></td><td style="width:36.548%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:22.677%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:34.775%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:14pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canaccord Genuity</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:14pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">William Blair</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:14pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Oppenheimer &#38; Co.</font></td></tr></table></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:78.086%;"><tr><td style="width:1.0%;"></td><td style="width:35.944%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.284%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:33.772%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:27pt;text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prospectus supplement dated June 1, 2020</font></div><div style="position:relative;width:100%;height:30.6pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_4"></div><hr style="page-break-after:always"><div style="height:18pt;width:100%;"><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS </font></div><div style="text-align:center;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Prospectus Supplement </font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:91.883%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.117%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Page</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_7" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">About this Prospectus Supplement</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">S-<a href="#ieed28d9304df4001833e3a91896e00cb_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;">ii</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_10" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Prospectus Supplement Summary</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">S-<a href="#ieed28d9304df4001833e3a91896e00cb_10" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;">1</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_13" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Risk Factors</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">S-<a href="#ieed28d9304df4001833e3a91896e00cb_13" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;">5</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_16" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Special Note Regarding Forward Looking Statements</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">S-<a href="#ieed28d9304df4001833e3a91896e00cb_16" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;">7</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_19" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Use of Proceeds</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">S-<a href="#ieed28d9304df4001833e3a91896e00cb_19" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;">9</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_22" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Dilution</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">S-<a href="#ieed28d9304df4001833e3a91896e00cb_22" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;">10</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_25" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Material United States Federal Income Tax Consequences to Non-U.S. Holders</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">S-<a href="#ieed28d9304df4001833e3a91896e00cb_25" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;">12</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_28" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Underwriting</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">S-<a href="#ieed28d9304df4001833e3a91896e00cb_28" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;">16</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_31" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Legal Matters</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">S-<a href="#ieed28d9304df4001833e3a91896e00cb_31" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;">21</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_34" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Experts</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">S-<a href="#ieed28d9304df4001833e3a91896e00cb_34" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;">21</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_37" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Where You Can Find More Information</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">S-<a href="#ieed28d9304df4001833e3a91896e00cb_37" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;">21</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_40" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Incorporation of Certain Information by Reference</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">S-<a href="#ieed28d9304df4001833e3a91896e00cb_40" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;">22</a></font></div></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Prospectus</font></div><div style="text-align:center;"><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:91.883%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.117%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Page</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_49" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">About This Prospectus</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a href="#ieed28d9304df4001833e3a91896e00cb_49" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;">ii</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_52" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Summary</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a href="#ieed28d9304df4001833e3a91896e00cb_52" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;">1</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_55" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Risk Factors</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a href="#ieed28d9304df4001833e3a91896e00cb_55" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;">4</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_58" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Special Note Regarding Forward-Looking Statements</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a href="#ieed28d9304df4001833e3a91896e00cb_58" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;">5</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_61" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Use of Proceeds</a> </font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a href="#ieed28d9304df4001833e3a91896e00cb_61" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;">7</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_64" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Description of Capital Stock</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a href="#ieed28d9304df4001833e3a91896e00cb_64" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;">8</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_67" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Description of Debt Securities</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a href="#ieed28d9304df4001833e3a91896e00cb_67" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;">12</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_70" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Description of Warrants</a> </font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a href="#ieed28d9304df4001833e3a91896e00cb_70" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;">18</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_73" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Legal Ownership of Securities</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a href="#ieed28d9304df4001833e3a91896e00cb_73" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;">21</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_76" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Plan of Distribution</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a href="#ieed28d9304df4001833e3a91896e00cb_76" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;">24</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_79" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Legal Matters</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a href="#ieed28d9304df4001833e3a91896e00cb_79" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;">26</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_82" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Experts</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a href="#ieed28d9304df4001833e3a91896e00cb_82" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;">26</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_85" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Where You Can Find More Information</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a href="#ieed28d9304df4001833e3a91896e00cb_85" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;">26</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_88" style="background-color:rgb(255,255,255, 0.0);color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Incorporation of Certain Information by Reference</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a href="#ieed28d9304df4001833e3a91896e00cb_88" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;">26</a></font></div></td></tr></table></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:93.577%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.623%;"><tr><td style="width:1.0%;"></td><td style="width:27.302%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:40.635%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:26.063%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">We and the underwriters have not authorized anyone to provide you with information different than that which is contained in or incorporated by reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectus that we have authorized for use in connection with this offering. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus supplement entitled &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference.&#8221; </font></div><div style="position:relative;width:100%;height:27pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-i</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_7"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ABOUT THIS PROSPECTUS SUPPLEMENT</font></div><div style="text-align:center;"><font><br></font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering of common stock and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus dated November 5, 2019, including the documents incorporated by reference therein, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference that was filed with the Securities and Exchange Commission (SEC) before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by reference in the accompanying prospectus&#8212;the statement in the document having the later date modifies or supersedes the earlier statement. You should assume that the information contained in this prospectus supplement is accurate as of the date on the front cover of this prospectus supplement only and that any information we have incorporated by reference or included in the accompanying prospectus is accurate only as of the date given in the document incorporated by reference or as of the date of the prospectus, as applicable, regardless of the time of delivery of this prospectus supplement or the accompanying prospectus or any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless the context indicates otherwise, as used in this prospectus supplement, the terms &#8220;Allogene,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Allogene Therapeutics, Inc. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This prospectus supplement, the accompanying prospectus and the information incorporated herein and therein by reference may include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus supplement or the accompanying prospectus are the property of their respective owners. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-ii</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_10"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="border-width:1.00pt;border-style:solid;border-color:#000000;padding:36.00pt 36.00pt 18.00pt 36.00pt;"><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PROSPECTUS SUPPLEMENT SUMMARY</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">This summary highlights selected information contained elsewhere or incorporated by reference in this prospectus supplement and the accompanying prospectus. This summary does not contain all the information you should consider before investing in our common stock. You should read and consider carefully the more detailed information in this prospectus supplement and the accompanying prospectus, including the factors described under the heading &#8220;Risk Factors&#8221; in this prospectus supplement, and under similar headings in other documents that are incorporated by reference in this prospectus supplement, and the financial and other information incorporated by reference in this prospectus supplement and the accompanying prospectus, as well as the information included in any free writing prospectus that we have authorized for use in connection with this offering, before making an investment decision. </font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Company Overview</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient&#8217;s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a deep pipeline of allogeneic chimeric antigen receptor (CAR) T cell product candidates targeting multiple promising antigens in a host of hematological malignancies and solid tumors. In collaboration with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (together, Servier), we are developing UCART19, ALLO-501 and ALLO-501A, CAR T cell product candidates targeting CD19. Servier is sponsoring two Phase 1 clinical trials of UCART19 in patients with relapsed&#47;refractory (R&#47;R) B-cell precursor acute lymphoblastic leukemia (ALL), one for adult patients (the CALM trial) and one for pediatric patients (the PALL trial). </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are sponsoring a Phase 1 clinical trial (the ALPHA trial) of ALLO-501 in patients with R&#47;R non-Hodgkin lymphoma (NHL). As described below, we reported initial data from the ALPHA trial at the American Society of Clinical Oncology (ASCO) annual meeting on May 29, 2020. We plan to continue the ALPHA trial to further explore and optimize treatment. We are using the clinical data from ALLO-501 to accelerate the development of the second-generation version of ALLO-501, known as ALLO-501A. We have removed rituximab recognition domains in ALLO-501A, which we believe will potentially facilitate treatment of more patients, as rituximab is a typical part of a treatment regimen for a patient with NHL. We initiated a Phase 1&#47;2 clinical trial for ALLO-501A (the ALPHA2 trial) in the second quarter of 2020.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We initiated a Phase 1 clinical trial (the UNIVERSAL trial) of ALLO-715, an allogeneic CAR T cell product candidate targeting B-cell maturation antigen (BCMA), in adult patients with R&#47;R multiple myeloma in the third quarter of 2019. We expect to report initial data from the UNIVERSAL trial in the fourth quarter of 2020. In addition, in January 2020, we entered into a clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. (SpringWorks) to evaluate ALLO-715 in combination with SpringWorks&#8217; investigational gamma secretase inhibitor, nirogacestat, in patients with R&#47;R multiple myeloma. We plan to initiate this combination trial in the second half of 2020, subject to regulatory clearance. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Due to the exceptional circumstances related to the COVID-19 pandemic, Servier halted recruitment in the CALM and PALL clinical trials earlier this year. Servier has recently resumed recruitment in the CALM and PALL clinical trials in an effort to complete previously planned cohorts. We are continuing to enroll patients in the ALPHA trial, ALPHA2 trial and UNIVERSAL trial, however, enrollment of new patients and the ability to conduct patient follow-up will be impacted by the COVID-19 pandemic. We have also closed our headquarters with our administrative employees continuing their work outside of our offices and limited the number of staff working onsite. Construction of our manufacturing facility in Newark, California, was interrupted for a period of time and may in the future be interrupted due to the COVID-19 pandemic. The exact timing of delays and overall impact of </font></div></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-1</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="border-width:1.00pt;border-style:solid;border-color:#000000;padding:36.00pt 36.00pt 18.00pt 36.00pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the COVID-19 pandemic to our business, preclinical studies and clinical trials is currently unknown, and we are monitoring the pandemic as it continues to rapidly evolve.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Phase 1 Results from the ALPHA Trial</font></div><div style="text-indent:27pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 29, 2020, we and Servier announced initial results from the ALPHA trial at the ASCO annual meeting. </font></div><div style="text-indent:27pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of the May 2020 data cutoff, 23 patients were enrolled and 22 patients received ALLO-501. One patient was removed from the study prior to lymphodepletion due to acute renal failure from urinary obstruction. The median time from enrollment to the start of therapy was five days. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the efficacy analysis, 19 out of 22 patients reached at least one month assessment as of the May 2020 data cutoff. Responses were observed across all cell doses and tumor histologies (diffuse large B-cell lymphoma and follicular lymphoma) with an overall response rate (ORR) of 63% and complete response (CR) rate of 37%. Higher dose ALLO-647 was associated with a higher CR rate of 50%, deeper lymphodepletion and delayed host T cell recovery. With a median follow-up of 3.8 months, nine of the 12 responding patients (75%) remained in response as of the data cutoff.</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.397%;"><tr><td style="width:1.0%;"></td><td style="width:10.214%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.749%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.749%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.749%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.749%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.749%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.749%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.749%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.543%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Cell Dose and LD regimen</font></div></td><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39mg ALLO-647</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90mg ALLO-647</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">All Patients<br>(N&#61;19)<br>(95% CI)</font></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">40 x 10</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">6</sup></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">CAR</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">+</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> cells</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">(N&#61;4)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">120 x 10</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">6</sup></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">CAR</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">+</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> cells</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">(N&#61;4)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">360 x 10</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">6</sup></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">CAR</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">+</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> cells</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">(N&#61;3)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">All 39mg ALLO-647</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%;">(N&#61;11)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">120 x 10</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">6</sup></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">CAR</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">+</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> cells</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">(N&#61;6)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">360 x 10</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">6</sup></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">CAR</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">+</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> cells</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">(N&#61;2)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">All 90mg ALLO-647</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%;">(N&#61;8)</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ORR, n (%) </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3 (75%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3 (75%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1 (33%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7 (64%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4 (67%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1(50%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5 (63%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">12&#47;19 (63%)</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(38%, 84%)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CR, n (%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1 (25%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1 (25%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1 (33%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3 (27%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4 (67%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0 (0%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4 (50%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">7&#47;19 (37%)</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(16%, 62%)</font></div></td></tr></table></div><div style="text-indent:27pt;"><font><br></font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">One of the ongoing responders is a patient with an initial partial response (PR) who progressed by month two. This patient achieved a CR after re-treatment with the same dose of ALLO-501 and a higher dose (90mg) of ALLO-647. This patient is reflected as a PR in the table above and not as a CR.  </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Included in the overall efficacy analysis are three patients who were refractory to prior autologous CAR T therapy (the best response of progressive disease or disease progression within three months). These patients were also refractory to allogeneic CAR T therapy. In CAR T na&#239;ve patients, the ORR was 75% and the CR rate was 44%.</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:87.019%;"><tr><td style="width:1.0%;"></td><td style="width:15.679%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:25.440%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:25.440%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:25.441%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">All Cell Doses + 39mg ALLO-647<br>(N10)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">120 x 10</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">6 </sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">and 360 x 10</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">6 </sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">CAR</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">+</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> cells + </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">90mg ALLO-647</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">(N&#61;6)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">All CAR T Na&#239;ve Patients</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">(N&#61;16)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ORR, n (%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7 (70%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5 (83%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">12&#47;16 (75%)</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(48%, 93%)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CR, n (%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3 (30%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4 (67%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">7&#47;16 (44%)</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(20%, 70%)</font></div></td></tr></table></div><div><font><br></font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No dose limiting toxicities, graft-vs-host disease, or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) was observed. </font></div></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-2</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="border-width:1.00pt;border-style:solid;border-color:#000000;padding:36.00pt 36.00pt 18.00pt 36.00pt;"><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.596%;"><tr><td style="width:1.0%;"></td><td style="width:29.034%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.793%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.793%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.793%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.793%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.794%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adverse Events of Interest</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Grade 1<br>N (%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Grade 2 <br>N (%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Grade 3<br>N (%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Grade 4<br>N (%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Grade 5<br>N (%)</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cytokine Release Syndrome</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2 (9%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4 (18%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1 (5%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ICANS</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Graft-versus-Host Disease</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Infection</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5 (23%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4 (18%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2 (9%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Infusion Reaction</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1 (5%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9 (41%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1 (5%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Neutropenia</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1 (5%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7 (32%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7 (32%)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</font></td></tr></table></div><div><font><br></font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cytokine release syndrome occurred in 32% of the patients, was mainly mild to moderate in severity, manageable with standard recommendations, and all events resolved within a maximum of seven days. Patients treated with 90mg ALLO-647 did not experience an increase in infection as compared to those treated with 39mg ALLO-647. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Four patients (18%) experienced serious adverse events (SAEs). One patient had Grade 2 pyrexia and Grade 2 cytomegalovirus (CMV) reactivation which resolved in two days and six days, respectively. One patient had Grade 3 rotavirus infection and Grade 3 hypokalemia which resolved in 15 days and two days, respectively. One patient had Grade 3 febrile neutropenia and Grade 3 hypotension which each resolved in two days. One patient had a Grade 3 upper GI hemorrhage which resolved in one day and Grade 3 CMV reactivation which resolved in 25 days. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Adverse events were observed across all dose levels of ALLO-501 and ALLO-647. SAEs were observed at ALLO-501 cell dose level 40 x 10</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">6</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and 120 x 10</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">6</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and at both dose levels of ALLO-647.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ALLO-501 and ALLO-501A use Cellectis S.A. technologies. Servier grants to us exclusive rights to ALLO-501 and ALLO-501A in the United States while Servier retains exclusive rights for all other countries.</font></div><div style="padding-right:0.7pt;text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Corporate Information </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We were incorporated in Delaware in November 2017. Our principal executive offices are located at 210 East Grand Avenue, South San Francisco, California 94080, and our telephone number is (650) 457-2700. Our corporate website address is www.allogene.com. Information contained on or accessible through our website is not part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only.</font></div></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-3</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="border-width:1.00pt;border-style:solid;border-color:#000000;padding:36.00pt 36.00pt 18.00pt 36.00pt;"><div style="padding-left:0.7pt;padding-right:0.7pt;text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">The Offering </font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:45.222%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:50.778%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Common stock offered by us</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,702,128 shares.</font></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option to purchase additional shares</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">We have granted the underwriters an option for a period of 30 days from the date of this prospectus supplement to purchase up to 1,755,319 of additional shares. </font></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Common stock to be outstanding immediately after this offering</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">136,964,665 shares (or 138,719,984 shares if the underwriters exercise in full their option to purchase additional shares).</font></div></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Use of proceeds</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">We estimate that the net proceeds to us from this offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, will be $517.9 million, or $595.7 million if the underwriters exercise in full their option to purchase additional shares.<br><br>We intend to use the net proceeds from this offering to fund research and development of product candidates and development programs, including the clinical trials of ALLO-501A and ALLO-715, as well as for working capital and other general corporate purposes. See &#8220;Use of Proceeds.&#8221;</font></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Risk factors</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing in our common stock involves a high degree of risk. See &#8220;Risk Factors&#8221; sections of this prospectus supplement and the documents incorporated by reference herein for a discussion of factors you should consider carefully before deciding to invest in our common stock.</font></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nasdaq Global Select Market symbol</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8220;ALLO&#8221;</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The number of shares to be outstanding immediately after this offering is based on 125,262,537 shares of our common stock outstanding as of March 31, 2020, and excludes as of that date&#58; </font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">11,627,389 shares of our common stock issuable upon the exercise of outstanding stock options, at a weighted-average exercise price of $15.56 per share&#59; </font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">2,534,671 shares of our common stock issuable upon vesting and settlement of outstanding restricted stock units&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">12,448,841 shares of common stock reserved for future issuance under our 2018 equity incentive plan (2018 Plan), as well as any future annual automatic increases in the number of shares of our common stock reserved for future issuance under the 2018 Plan&#59; and </font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">3,424,952 shares of our common stock reserved for issuance under our 2018 employee stock purchase plan (ESPP), as well as any future annual automatic increases in the number of shares of our common stock reserved for issuance under the ESPP. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Except as otherwise indicated, all information in this prospectus supplement assumes no exercise by the underwriters of their option to purchase additional shares. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Entities affiliated with our Executive Chairman, Arie Belldegrun, M.D., FACS, have agreed to purchase an aggregate of 146,382 shares of the common stock offered in this offering at the price offered to the public.</font></div></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-4</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_13"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RISK FACTORS </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investing in our common stock involves a high degree of risk. Our business, prospects, financial condition or operating results could be materially adversely affected by the risks identified below and in the documents incorporated by reference in this prospectus supplement, as well as other risks not currently known to us or that we currently consider immaterial. The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. You should consider carefully the risks described below and discussed in our Quarterly Report on Form 10-Q filed on May 6, 2020, which is incorporated by reference in this prospectus supplement in its entirety, together with the information contained in the other documents incorporated by reference into this prospectus supplement and the accompanying prospectus in their entirety, and other documents that we file from time to time with the SEC.</font></div><div style="text-indent:27pt;text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to this Offering </font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Management will have broad discretion as to the use of the net proceeds from this offering, and we may not use the proceeds effectively.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management will have broad discretion in the application of the net proceeds we receive from this offering, including for any of the purposes described in the section of this prospectus supplement entitled &#8220;Use of Proceeds,&#8221; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. Our failure to apply these funds effectively could have a material adverse effect on our business, delay the development of our product candidates and cause the price of our common stock to decline. </font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If you purchase the common stock sold in this offering, you will experience immediate and substantial dilution in your investment. You will experience further dilution if we issue additional equity securities in the future.  Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since the price per share of our common stock being offered is substantially higher than the net tangible book value per share of our common stock, you will suffer substantial dilution with respect to the net tangible book value of the common stock you purchase in this offering. Based on the public offering price of $47.00 per share, and our net tangible book value as of March 31, 2020, if you purchase shares of common stock in this offering, you will suffer immediate and substantial dilution of $38.79 per share with respect to the net tangible book value of the common stock. See &#8220;Dilution&#8221; for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, we have a significant number of stock options and restricted stock units outstanding. To the extent that outstanding stock options have been or may be exercised or restricted stock units have been or may be settled, or other shares are issued, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders or result in downward pressure on the price of our common stock. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, sales of a substantial number of shares of our outstanding common stock in the public market could occur at any time. While our directors and officers, and certain of our stockholders executed lockups with the underwriters in this offering restricting the sale of their shares of our common stock, certain stockholders that executed lockups are permitted to sell up to 1.5 million of our shares during the lockup period. These sales, including sales by the aforementioned stockholders, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. Significant portions of our outstanding shares of common stock are held by a relatively small number of </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-5</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">stockholders. Sales by our stockholders of a substantial number of shares, or the expectation that such sales may occur, could significantly reduce the market price of our common stock. </font></div><div style="text-indent:27pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-6</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_16"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Statements contained in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein that are not strictly historical in nature are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the Securities Act), and within the meaning of Section&#160;21E of the Exchange Act of 1934, as amended (the Exchange Act). These forward-looking statements are subject to the &#8220;safe harbor&#8221; created by Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act and may include, but are not limited to, statements about&#58;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the success, cost, timing and potential indications of our product development activities and clinical trials&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the timing of our planned investigational new drug application submissions to the U.S. Food and Drug Administration for our product candidates&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the timing of the initiation, enrollment and completion of planned clinical trials in the United States and foreign countries&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the expected or potential impact of the COVID-19 pandemic on our operations&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to obtain and maintain regulatory approval of our product candidates in any of the indications for which we plan to develop them, and any related restrictions, limitations, and&#47;or warnings in the label of an approved product candidate&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to obtain funding for our operations, including funding necessary to complete the clinical trials of any of our product candidates&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our plans to research, develop and commercialize our product candidates&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to attract and retain collaborators with development, regulatory and commercialization expertise&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the size of the markets for our product candidates, and our ability to serve those markets&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to successfully commercialize our product candidates&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the rate and degree of market acceptance of our product candidates&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to develop and maintain sales and marketing capabilities, whether alone or with potential future collaborators&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">regulatory developments in the United States and foreign countries&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to contract with and the performance of our and our collaborators&#8217; third-party suppliers and manufacturers&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to develop and successfully operate our own manufacturing facility&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the success of competing therapies that are or become available&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to attract and retain key scientific or management personnel&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our use of cash and other resources, including our expected use of the proceeds from our initial public offering and from this offering&#59; and</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and our ability to operate our business without infringing on the intellectual property rights of others.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-7</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In some cases, you can identify forward-looking statements by terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;goal,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; the negative of these words and words or similar expressions intended to identify forward-looking statements. These statements reflect our views as of the date on which they were made with respect to future events and are based on assumptions and subject to risks and uncertainties. The underlying information and expectations are likely to change over time. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date the statement is made, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Given these uncertainties, you should not place undue reliance on these forward-looking statements as actual events or results may differ materially from those projected in the forward-looking statements due to various factors, including, but not limited to, those set forth under the heading &#8220;Risk Factors&#8221; in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein or any free writing prospectus that we authorize for use in connection with this offering. These forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements contained in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein by these cautionary statements. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. Before deciding to purchase our common stock in this offering, you should carefully consider the risk factors discussed herein or incorporated by reference, in addition to the other information set forth in this prospectus supplement, the accompanying prospectus, any free writing prospectus we authorize for use in connection with this offering and the documents incorporated by reference.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-8</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_19"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">USE OF PROCEEDS  </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We estimate that we will receive net proceeds of approximately $517.9 million from the sale of shares of our common stock offered by us in this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise their option to purchase additional shares of our common stock in full, we estimate that the net proceeds to us will be approximately $595.7 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We intend to use the net proceeds from this offering to fund research and development of product candidates and development programs, including the clinical trials of ALLO-501A and ALLO-715, as well as for working capital and other general corporate purposes. We may also use a portion of the net proceeds to in-license, invest in or acquire businesses, assets or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The amounts and timing of these expenditures will depend on a number of factors, such as the timing and progress of our clinical trials and our other research and development efforts, the timing and progress of any partnering efforts and the competitive environment for our product candidates. As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses of the net proceeds from this offering. Accordingly, we will retain broad discretion over the use of such proceeds. Pending the use of the net proceeds from this offering as described above, we intend to invest the net proceeds in investment-grade, interest-bearing instruments.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-9</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_22"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">DILUTION</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Investors purchasing shares of our common stock in this offering will experience immediate and substantial dilution in the pro forma net tangible book value of their shares of common stock. Dilution in net tangible book value represents the difference between the public offering price per share and the adjusted net tangible book value per share of our common stock immediately after this offering. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The historical net tangible book value of our common stock as of March 31, 2020 was $606.5 million, or $4.84 per share. Historical net tangible book value per share of our common stock represents our total tangible assets (total assets less intangible assets) less total liabilities, divided by the number of shares of common stock outstanding as of that date. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">After giving effect to the issuance of 11,702,128 shares of common stock at the public offering price of $47.00 per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of March 31, 2020 would have been approximately $1,124.4 million, or $8.21 per share of common stock. This represents an immediate increase in net tangible book value of $3.37 per share to existing stockholders and an immediate dilution of $38.79 per share to new investors purchasing our common stock in this offering. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table illustrates this dilution on a per share basis to new investors&#58; </font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:75.884%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.057%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.059%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-10pt;padding-left:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Public offering price per share</font></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47.00&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-10pt;padding-left:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Historical net tangible book value per share as of March 31, 2020 </font></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.84&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:21pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Increase in net tangible book value per share attributable to new investors </font></div><div style="padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">purchasing shares in this offering </font></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.37&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-10pt;padding-left:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As adjusted net tangible book value per share after giving effect to this offering</font></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.21&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-10pt;padding-left:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dilution per share to new investors participating in this offering </font></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.79&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the underwriters exercise their option in full to purchase an additional 1,755,319 shares of common stock in this offering, the as adjusted net tangible book value per share after the offering would be $8.67 per share, the increase in the net tangible book value per share to existing stockholders would be $3.83</font><font style="background-color:rgb(255,255,255, 0.0);color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">per share and the dilution to new investors purchasing our common stock in this offering would be $38.33 per share. </font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The above discussion and table are based on 125,262,537 shares of our common stock outstanding as of March 31, 2020, and excludes as of that date&#58; </font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">11,627,389 shares of our common stock issuable upon the exercise of outstanding stock options, at a weighted-average exercise price of $15.56 per share&#59; </font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">2,534,671 shares of our common stock issuable upon vesting and settlement of outstanding restricted stock units&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">12,448,841 shares of common stock reserved for future issuance under the 2018 Plan, as well as any future annual automatic increases in the number of shares of our common stock reserved for future issuance under the 2018 Plan&#59; and </font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">3,424,952 shares of our common stock reserved for issuance under the ESPP, as well as any future annual automatic increases in the number of shares of our common stock reserved for issuance under the ESPP. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital by issuing equity securities or convertible debt, your ownership will be further diluted. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-10</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To the extent that existing options are exercised or restricted stock units vest, new options or restricted stock units are issued under our share-based compensation plans or we issue additional shares of common stock under the ESPP in the future, there will be further dilution to investors participating in this offering. </font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-11</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_25"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of the material U.S. federal income tax consequences to non-U.S. holders (as defined below) of the acquisition, ownership and disposition of our common stock issued pursuant to this offering. This discussion is not a complete analysis of all potential U.S. federal income tax consequences relating thereto, does not address the potential application of the Medicare contribution tax on net investment income, and does not address any estate or gift tax consequences or any tax consequences arising under any state, local or foreign tax laws, or any other U.S. federal tax laws. This discussion is based on the Internal Revenue Code of 1986, as amended, or the Code, and applicable Treasury Regulations promulgated thereunder, judicial decisions and published rulings and administrative pronouncements of the Internal Revenue Service, or IRS, all as in effect as of the date hereof. These authorities are subject to differing interpretations and may change, possibly retroactively, resulting in U.S. federal income tax consequences different from those discussed below. We have not requested a ruling from the IRS with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This discussion is limited to non-U.S. holders who purchase our common stock pursuant to this offering and who hold our common stock as a &#8220;capital asset&#8221; within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all of the U.S. federal income tax consequences that may be relevant to a particular holder in light of such holder&#8217;s particular circumstances. This discussion also does not consider any specific facts or circumstances that may be relevant to holders subject to special rules under the U.S. federal income tax laws, including&#58;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">certain former citizens or long-term residents of the United States&#59; </font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">&#8220;controlled foreign corporations&#59;&#8221;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">&#8220;passive foreign investment companies&#59;&#8221;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">corporations that accumulate earnings to avoid U.S. federal income tax&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">banks, financial institutions, investment funds, insurance companies, brokers, dealers or traders in securities&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">tax-exempt organizations and governmental organizations&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">tax-qualified retirement plans&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">&#8220;qualified foreign pension funds&#8221; as defined in Section 897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">persons subject to the alternative minimum tax&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">persons that own, or have owned, actually or constructively, more than 5% of our common stock at any time&#59; </font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">accrual-method taxpayers subject to special tax accounting rules under Section 451(b) of the Code&#59; and</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">persons holding our common stock as part of a hedging or conversion transaction or straddle, or synthetic security, or a constructive sale, or other risk reduction strategy or integrated investment. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes holds our common stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Partnerships holding our common stock and the partners in such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax consequences to them of holding and disposing of our common stock.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-12</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL OR FOREIGN TAX LAWS AND ANY OTHER U.S. FEDERAL TAX LAWS.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Definition of Non-U.S. Holder</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For purposes of this discussion, a non-U.S. holder is any beneficial owner of our common stock that is not a &#8220;U.S. person&#8221; or a partnership (including any entity or arrangement treated as a partnership) for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following&#58;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">an individual who is a citizen or resident of the United States&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">a corporation (or entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof or the District of Columbia&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">an estate, the income of which is subject to U.S. federal income tax regardless of its source&#59; or</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">a trust (1) whose administration is subject to the primary supervision of a U.S. court and which has one or more U.S. persons who have the authority to control all substantial decisions of the trust or (2) that has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Distributions on Our Common Stock</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have never declared or paid any cash dividends on our capital stock and we do not intend to pay cash dividends on our common stock for the foreseeable future. However, if we make cash or other property distributions on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and will first be applied against and reduce a holder&#8217;s tax basis in our common stock, but not below zero. Any excess will be treated as gain realized on the sale or other disposition of our common stock and will be treated as described under the section titled &#8220;&#8212;Gain on Disposition of Our Common Stock&#8221; below.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the discussions below regarding effectively connected income, backup withholding and Sections 1471 through 1474 of the Code (commonly referred to as FATCA), dividends paid to a non-U.S. holder of our common stock generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends or such lower rate specified by an applicable income tax treaty. To receive the benefit of a reduced treaty rate, a non-U.S. holder must furnish us or our paying agent with a valid IRS Form W-8BEN or IRS Form W-8BEN-E (or applicable successor form) and satisfy applicable certification and other requirements. This certification must be provided to us or our paying agent before the payment of dividends and must be updated periodically. If the non-U.S. holder holds the stock through a financial institution or other agent acting on the non-U.S. holder&#8217;s behalf, the non-U.S. holder will be required to provide appropriate documentation to the agent, which then will be required to provide certification to us or our paying agent, either directly or through other intermediaries.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-U.S. holders that do not provide the required certification on a timely basis, but that qualify for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If a non-U.S. holder holds our common stock in connection with the conduct of a trade or business in the United States, and dividends paid on our common stock are effectively connected with such holder&#8217;s U.S. trade or business (and are attributable to such holder&#8217;s permanent establishment in the United States if required by an applicable tax treaty), the non-U.S. holder will be exempt from U.S. federal withholding tax. To claim the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-13</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">exemption, the non-U.S. holder must generally furnish a valid IRS Form W-8ECI (or applicable successor form) to the applicable withholding agent.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">However, any such effectively connected dividends paid on our common stock generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. A non-U.S. holder that is a foreign corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. Non-U.S. holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Gain on Disposition of Our Common Stock</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the discussions below regarding backup withholding and FATCA, a non-U.S. holder generally will not be subject to U.S. federal income tax on any gain realized on the sale or other disposition of our common stock, unless&#58;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the gain is effectively connected with the non-U.S. holder&#8217;s conduct of a trade or business in the United States, and if required by an applicable income tax treaty, is attributable to a permanent establishment maintained by the non-U.S. holder in the United States&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the non-U.S. holder is a nonresident alien individual present in the United States for 183 days or more during the taxable year of the disposition, and certain other requirements are met&#59; or</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our common stock constitutes a &#8220;United States real property interest&#8221; by reason of our status as a United States real property holding corporation, or USRPHC, for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the disposition or the non-U.S. holder&#8217;s holding period for our common stock, and our common stock is not &#8220;regularly traded&#8221; on an established securities market (as defined by applicable Treasury Regulation).</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Determining whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our other trade or business assets and our foreign real property interests. We believe that we are not currently and do not anticipate becoming a USRPHC for U.S. federal income tax purposes, although there can be no assurance we will not in the future become a USRPHC. If we are or become a USRPHC and the &#8220;regularly traded&#8221; exception noted above does not apply to the disposition, such non-U.S. holder will generally be taxed on any gain in the same manner as gain that is effectively connected with the conduct of a U.S. trade or business, except that the branch profits tax generally will not apply. Prospective investors are encouraged to consult their own tax advisors regarding the possible consequences to them if we are, or were to become, a USRPHC.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. A non-U.S. holder that is a foreign corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. Gain described in the second bullet point above will be subject to U.S. federal income tax at a flat 30% rate (or such lower rate specified by an applicable income tax treaty), but may be offset by certain U.S.-source capital losses (even though the individual is not considered a resident of the United States), provided that the non-U.S. holder has timely filed U.S. federal income tax returns with respect to such losses. Non-U.S. holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Information Reporting and Backup Withholding</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Annual reports are required to be filed with the IRS and provided to each non-U.S. holder indicating the amount of dividends on our common stock paid to such holder and the amount of any tax withheld with respect to those dividends. These information reporting requirements apply even if no withholding was required because the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-14</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">dividends were effectively connected with the holder&#8217;s conduct of a U.S. trade or business, or withholding was reduced or eliminated by an applicable income tax treaty. This information also may be made available under a specific treaty or agreement with the tax authorities in the country in which the non-U.S. holder resides or is established. Backup withholding, currently at a 24% rate, generally will not apply to payments to a non-U.S. holder of dividends on or the gross proceeds of a disposition of our common stock provided the non-U.S. holder furnishes the required certification for its non-U.S. status, such as by providing a valid IRS Form W-8BEN, IRS Form W-8BEN-E or IRS Form W-8ECI, or certain other requirements are met. Backup withholding may apply if the payor has actual knowledge, or reason to know, that the holder is a U.S. person who is not an exempt recipient.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Backup withholding is not an additional tax. If any amount is withheld under the backup withholding rules, the non-U.S. holder should consult with a U.S. tax advisor regarding the possibility of and procedure for obtaining a refund or a credit against the non-U.S. holder&#8217;s U.S. federal income tax liability, if any.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Withholding on Foreign Entities</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">FATCA imposes a U.S. federal withholding tax of 30% on certain payments made to a &#8220;foreign financial institution&#8221; (as specially defined under these rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding certain U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or an exemption applies. FATCA also generally imposes a U.S. federal withholding tax of 30% on certain payments made to a non-financial foreign entity unless such entity provides the withholding agent a certification identifying certain direct and indirect U.S. owners of the entity or an exemption applies. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. Under certain circumstances, a non-U.S. holder might be eligible for refunds or credits of such taxes. FATCA currently applies to dividends paid on our common stock. Under applicable Treasury Regulations and administrative guidance, withholding under FATCA would have applied to payments of gross proceeds from the sale or other disposition of stock on or after January 1, 2019, but under proposed regulations (the preamble to which specifies that taxpayers are permitted to rely on such proposed regulations pending finalization), no withholding would apply with respect to payments of gross proceeds.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prospective investors are encouraged to consult with their own tax advisors regarding the potential implications of FATCA on their investment in our common stock.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-15</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_28"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">UNDERWRITING  </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We and the underwriters named below have entered into an underwriting agreement with respect to the shares being offered.  Subject to certain conditions, each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs &#38; Co. LLC, Jefferies LLC and Cowen and Company, LLC are the representatives of the underwriters.</font></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:80.211%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.789%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Underwriters</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Number of Shares</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goldman Sachs &#38; Co. LLC</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,347,777</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jefferies LLC</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,755,633</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cowen and Company, LLC</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,755,633</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Piper Sandler &#38; Co.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">661,620</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canaccord Genuity LLC</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">411,150</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">William Blair &#38; Company, L.L.C.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">411,150</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Oppenheimer &#38; Co. Inc.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">359,165</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:58.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Total</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,702,128</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other than the shares covered by the option described below unless and until this option is exercised.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The underwriters have an option to buy up to an additional 1,755,319 shares of our common stock from us to cover sales by the underwriters of a greater number of shares than the total number set forth in the table above.  They may exercise that option for 30 days.  If any shares are purchased pursuant to this option, the underwriters will severally purchase shares in approximately the same proportion as set forth in the table above.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters by us.  Such amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase 1,755,319 additional shares.</font></div><div style="text-indent:27pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Paid by Us</font></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:67.858%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.070%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.072%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">No Exercise</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Full Exercise</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Per Share</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7025&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7025&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,625,001&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,368,751&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Shares sold by the underwriters to the public will initially be offered at the public offering price set forth on the cover of this prospectus.  Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $1.4805 per share from the public offering price.  After the initial offering of the shares, the representatives may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#8217; right to reject any order in whole or in part. We have agreed to reimburse the underwriters for certain of their expenses in an amount up to $25,000.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We and our officers, directors, and certain of our stockholders have agreed with the underwriters not to dispose of or hedge any of our common stock or securities convertible into or exchangeable for shares of our common stock during the period from the date of this prospectus continuing through the date 60 days after the date of this prospectus, except with the prior written consent of the representatives and subject to certain exceptions including an exception allowing certain stockholders to dispose of or hedge up to 1.5 million shares of our common stock.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the offering, the underwriters may purchase and sell shares of common stock in the open market.  These transactions may include short sales, stabilizing transactions and purchases to cover positions created </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-16</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">by short sales.  Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases.  A &#8220;covered short position&#8221; is a short position that is not greater than the amount of additional shares for which the underwriters&#8217; option described above may be exercised.  The underwriters may cover any covered short position by either exercising their option to purchase additional shares or purchasing shares in the open market.    In determining the source of shares to cover the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional shares pursuant to the option described above.  &#8220;Naked&#8221; short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised.  The underwriters must cover any such naked short position by purchasing shares in the open market.  A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in the offering.  Stabilizing transactions consist of various bids for or purchases of common stock made by the underwriters in the open market prior to the completion of the offering. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions.  </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a decline in the market price of our common stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the common stock.  As a result, the price of the common stock may be higher than the price that otherwise might exist in the open market.  The underwriters are not required to engage in these activities and may end any of these activities at any time.  These transactions may be effected on The Nasdaq Global Select Market, in the over-the-counter market or otherwise.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">European Economic Area and United Kingdom</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In relation to each Member State of the European Economic Area and the United Kingdom (each a Relevant State), no common shares (the Shares) have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the Shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation), except that offers of Shares may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation&#58;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt;">to any legal entity which is a qualified investor as defined under the Prospectus Regulation&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer&#59; or </font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt;">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">provided that no such offer of Shares shall require the company or any representative to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to any Shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any Shares to be offered so as to enable an investor to decide to purchase or subscribe for any Shares, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017&#47;1129.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-17</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">United Kingdom</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each underwriter has represented and agreed that&#58;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt;">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000 (as amended, the FSMA)) received by it in connection with the issue or sale of the shares in circumstances in which Section 21(1) of the FSMA does not apply to the company or the selling stockholders&#59; and</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the shares in, from or otherwise involving the United Kingdom.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Canada</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions, and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption form, or in a transaction not subject to, the prospectus requirements of applicable securities laws.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this offering memorandum (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory of these rights or consult with a legal advisor.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Hong Kong</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The shares may not be offered or sold in Hong Kong by means of any document other than (i) in circumstances which do not constitute an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong) (Companies (Winding Up and Miscellaneous Provisions) Ordinance) or which do not constitute an invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (Securities and Futures Ordinance), or (ii) to &#34;professional investors&#34; as defined in the Securities and Futures Ordinance and any rules made thereunder, or (iii) in other circumstances which do not result in the document being a &#34;prospectus&#34; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#34;professional investors&#34; in Hong Kong as defined in the Securities and Futures Ordinance and any rules made thereunder.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Singapore</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-18</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor (as defined under Section 4A of the Securities and Futures Act, Chapter 289 of Singapore (the SFA)) under Section 274 of the SFA, (ii) to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to conditions set forth in the SFA.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Where the shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is  a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor, the securities (as defined in Section 239(1) of the SFA) of that corporation shall not be transferable for 6 months after that corporation has acquired the shares under Section 275 of the SFA except&#58; (1) to an institutional investor under Section 274 of the SFA or to a relevant person (as defined in Section 275(2) of the SFA), (2) where such transfer arises from an offer in that corporation&#8217;s securities pursuant to Section 275(1A) of the SFA, (3) where no consideration is or will be given for the transfer, (4) where the transfer is by operation of law, (5) as specified in Section 276(7) of the SFA, or (6) as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore (Regulation 32). </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Where the shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is a trust (where the trustee is not an accredited investor (as defined in Section 4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an accredited investor, the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferable for 6 months after that trust has acquired the shares under Section 275 of the SFA except&#58; (1) to an institutional investor under Section 274 of the SFA or to a relevant person (as defined in Section 275(2) of the SFA), (2) where such transfer arises from an offer that is made on terms that such rights or interest are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each transaction (whether such amount is to be paid for in cash or by exchange of securities or other assets),  (3) where no consideration is or will be given for the transfer, (4) where the transfer is by operation of law, (5) as specified in Section 276(7) of the SFA, or (6) as specified in Regulation 32.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Japan</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The securities have not been and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No. 25 of 1948, as amended), or the FIEA. The securities may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident of Japan (including any person resident in Japan or any corporation or other entity organized under the laws of Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of Japan, except pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any relevant laws and regulations of Japan.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial activities and services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the issuer and to persons and entities with relationships with the issuer, for which they received or will receive customary fees and expenses.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the ordinary course of their various business activities, the underwriters and their respective affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and&#47;or instruments of the issuer (directly, as collateral securing other obligations or otherwise) and&#47;or persons and entities with relationships with the issuer. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and&#47;or publish or express independent research views in respect of such assets, securities or instruments and may at any </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-19</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">time hold, or recommend to clients that they should acquire, long and&#47;or short positions in such assets, securities and instruments.  </font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-20</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_31"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LEGAL MATTERS</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The validity of the shares of common stock being offered by this prospectus supplement will be passed upon for us by Cooley LLP, San Diego, California. The underwriters are being represented by Latham &#38; Watkins LLP, Menlo Park, California.</font></div><div><font><br></font></div><div id="ieed28d9304df4001833e3a91896e00cb_34"></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXPERTS</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ernst &#38; Young LLP, independent registered public accounting firm, has audited our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019, and the effectiveness of our internal control over financial reporting as of December 31, 2019, as set forth in their reports, which are incorporated by reference in this prospectus supplement and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst &#38; Young LLP&#8217;s report, given on their authority as experts in accounting and auditing.</font></div><div><font><br></font></div><div id="ieed28d9304df4001833e3a91896e00cb_37"></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">WHERE YOU CAN FIND MORE INFORMATION</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 we filed with the SEC under the Securities Act and do not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus supplement or the accompanying prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference in this prospectus supplement and the accompanying prospectus for a copy of such contract, agreement or other document. Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#8217;s website at http&#58;&#47;&#47;www.sec.gov. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-21</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_40"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_4" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Table of Contents</a></font></div></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The SEC allows us to &#8220;incorporate by reference&#8221; the information we file with it, which means that we can disclose important information to you by referring you to those documents. Information incorporated by reference is part of this prospectus supplement and the accompanying prospectus. Later information filed with the SEC will update and supersede this information. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We incorporate by reference the documents listed below and any future filings made by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus supplement until the termination of the offering of the shares covered by this prospectus supplement (other than any information furnished under Item 2.02 or Item 7.01 of any Current Report on Form 8-K and exhibits filed on such form that are related to such items and other portions of documents that are furnished, but not filed, pursuant to applicable rules promulgated by the SEC)&#58; </font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our Annual Report on </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1737287/000173728720000012/allo-20191231.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Form 10-K</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for the fiscal year ended December 31, 2019, filed with the SEC on February 27, 2020&#59; </font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the information specifically incorporated by reference into our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 from our definitive proxy statement on </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="https://www.sec.gov/Archives/edgar/data/1737287/000173728720000021/allo-20200423xdef14axproxy.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule&#160;14A </a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(other than information furnished rather than filed), filed with the SEC on April&#160;23, 2020&#59; </font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1737287/000173728720000027/allo-20200331.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">May 6, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our Current Reports on Form 8-K filed with the SEC on </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1737287/000173728720000017/allo-20200327.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">March 27, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1737287/000173728720000029/allo-20200529.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">May 29, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; and </font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the description of our common stock, which is registered under Section 12 of the Exchange Act, in our registration statement on&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518294785/d616804d8a12b.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Form 8-A</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, filed with the SEC on October 5, 2018, including all amendments or reports filed for the purpose of updating such description. </font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You may request a copy of these filings at no cost, by contacting us at the following address or telephone number&#58; </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Allogene Therapeutics, Inc. </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">210 East Grand Avenue</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">South San Francisco, CA 94080</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(650) 457-2700</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accordance with Rule 412 of the Securities Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-22</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_43"></div><hr style="page-break-after:always"><div style="height:27pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;">PROSPECTUS</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><img alt="image_01.jpg" src="image_01.jpg" style="height:64px;width:272px;"></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Common Stock</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Preferred Stock</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Debt Securities</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Warrants</font></div><div><font><br></font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we may offer and sell any combination of shares of our common stock, shares of our preferred stock, debt securities and warrants to purchase any of such securities in one or more offerings as described in this prospectus. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable antidilution provisions.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This prospectus provides a general description of the securities we may offer. Each time we offer securities, we will specify in an accompanying prospectus supplement the terms of the securities being offered. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">This prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our common stock is traded on the Nasdaq Global Select Market under the symbol &#8220;ALLO.&#8221; On November 1, 2019, the last reported sale price of our common stock was $28.94 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on the Nasdaq Global Select Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement. We are an &#8220;emerging growth company&#8221; as defined under the federal securities laws and, as such, have elected to comply with certain reduced public company reporting requirements.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may sell these securities directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section titled &#8220;Plan of Distribution&#8221; in this prospectus. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font></div><div><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The date of this prospectus is&#160;November 5, 2019.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</font></div><div style="position:relative;width:100%;height:27pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_46"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:89.013%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.987%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_49" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">ABOUT THIS PROSPECTUS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_49" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">ii</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_52" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">SUMMARY</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_52" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">1</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_55" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">RISK FACTORS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_55" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">4</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_58" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_58" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">5</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_61" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">USE OF PROCEEDS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_61" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">7</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_64" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">DESCRIPTION OF CAPITAL STOCK</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_64" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">8</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_67" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">DESCRIPTION OF DEBT SECURITIES</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_67" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">12</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_70" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">DESCRIPTION OF WARRANTS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_70" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">18</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_73" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">LEGAL OWNERSHIP OF SECURITIES</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_73" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">21</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_76" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">PLAN OF DISTRIBUTION</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_76" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">24</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_79" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">LEGAL MATTERS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_79" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">26</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_82" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">EXPERTS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_82" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">26</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_85" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">WHERE YOU CAN FIND MORE INFORMATION</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_85" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">26</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_88" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#ieed28d9304df4001833e3a91896e00cb_88" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">26</a></font></div></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">i</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_49"></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ABOUT THIS PROSPECTUS</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This prospectus is a part of an automatic registration statement on Form S-3 that we filed with the U.S. Securities and Exchange Commission (SEC) utilizing a &#8220;shelf&#8221; registration process as a &#8220;well-known seasoned issuer,&#8221; as defined in Rule 405 under the Securities Act of 1933, as amended (the Securities Act). Under this shelf registration process, we may offer and sell from time to time in one or more offerings the securities described in this prospectus. No limit exists on the aggregate number or amount of securities we may sell pursuant to the registration statement.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This prospectus provides you with a general description of the securities we may offer. Each time we offer securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of these securities and offerings. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading &#8220;Incorporation of Certain Information by Reference,&#8221; before investing in any of the securities offered.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Neither we, nor any agent, underwriter or dealer has authorized any person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on behalf of us or to which we have referred you. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date.</font></div><div style="text-indent:27pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#8220;Where You Can Find More Information.&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">ii</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_52"></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="border-width:1.00pt;border-style:solid;border-color:#000000;padding:18.00pt 18.00pt 18.00pt 18.00pt;"><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SUMMARY</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This summary highlights selected information from this prospectus and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless the context requires otherwise, references in this prospectus to the &#8220;Company,&#8221; &#8220;Allogene,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Allogene Therapeutics, Inc.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Company Overview</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient&#8217;s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Corporate Information</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We were incorporated in Delaware in November 2017. Our principal executive offices are located at 210 East Grand Avenue, South San Francisco, California 94080, and our telephone number is (650)&#160;457-2700. Our corporate website address is www.allogene.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This prospectus contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">The Securities We May Offer</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may offer shares of our common stock, shares of our preferred stock, debt securities and warrants to purchase any of such securities, from time to time in one or more offerings under this prospectus, together with any applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at the time of the relevant offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable&#58;</font></div></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">1</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="border-width:1.00pt;border-style:solid;border-color:#000000;padding:18.00pt 18.00pt 18.00pt 18.00pt;"><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.071%;"><tr><td style="width:1.0%;"></td><td style="width:1.431%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.431%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:91.138%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">designation or classification&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">aggregate principal amount or aggregate offering price&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">maturity, if applicable&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">original issue discount, if any&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">rates and times of payment of interest or dividends, if any&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">redemption, conversion, exchange or sinking fund terms, if any&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ranking, if applicable&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">restrictive covenants, if any&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">voting or other rights, if any&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">important U.S. federal income tax considerations.</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may sell the securities directly to investors or through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the applicable prospectus supplement&#58;</font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.071%;"><tr><td style="width:1.0%;"></td><td style="width:1.431%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.431%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:91.138%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the names of those underwriters or agents&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">applicable fees, discounts and commissions to be paid to them&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">details regarding over-allotment options, if any&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the estimated net proceeds to us.</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We may issue shares of our common stock from time to time. Holders of our common stock are entitled to one vote per share for the election of directors and on all other matters that require stockholder approval. Subject to any preferential rights of any then outstanding preferred stock, in the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in the assets remaining after payment of liabilities and the liquidation preferences of any then outstanding preferred stock. Our common stock does not carry any preemptive rights enabling a holder to subscribe for, or receive shares of, any class of our common stock or any other securities convertible into shares of any class of our common stock, or any redemption rights.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Preferred Stock</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may issue shares of our preferred stock from time to time, in one or more series. Under our amended and restated certificate of incorporation, our board of directors has the authority, without further action by stockholders, to designate up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges, qualifications and restrictions granted to or imposed upon the preferred stock, including dividend rights, conversion rights, voting rights, rights and terms of redemption, liquidation preference and sinking fund terms, any or all of which may be greater than the rights of the common stock. To date, none of the 10,000,000 authorized shares of preferred stock have been designated by our board of directors. Convertible preferred stock will be convertible into our common stock or exchangeable for our other securities. Conversion may be mandatory or at the option of the holders of our preferred stock and would be at prescribed conversion rates.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will fix the rights, preferences, privileges, qualifications and restrictions of the preferred stock of each series that we sell under this prospectus and applicable prospectus supplements in the certificate of designation relating to that series. We will incorporate by reference into the registration statement of which this prospectus is a part the form of any certificate </font></div></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">2</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="border-width:1.00pt;border-style:solid;border-color:#000000;padding:18.00pt 18.00pt 18.00pt 18.00pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of designation that describes the terms of the series of preferred stock we are offering before the issuance of the related series of preferred stock. We urge you, however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Debt Securities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into our common stock or preferred stock. Conversion may be mandatory or at the holder&#8217;s option and would be at prescribed conversion rates.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The debt securities will be issued under one or more documents called indentures, which are contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. A form of indenture has been filed as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Warrants</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may issue warrants for the purchase of common stock, preferred stock and&#47;or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and&#47;or debt securities, and the warrants may be attached to or separate from these securities. In this prospectus, we have summarized certain general features of the warrants. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants. Forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants being offered have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental warrant agreements and forms of warrant certificates will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will evidence each series of warrants by warrant certificates that we will issue. Warrants may be issued under an applicable warrant agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered.</font></div></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">3</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_55"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RISK FACTORS</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our most recent Annual Report on Form 10-K, as updated by our quarterly and other reports and documents that are incorporated by reference into this prospectus and the applicable prospectus supplement, before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">4</font></div><div><font><br></font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_58"></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Statements contained in this prospectus, the applicable prospectus supplement and in the documents incorporated by reference herein and therein that are not strictly historical in nature are forward-looking statements within the meaning of Section&#160;27A of the Securities Act, and within the meaning of Section&#160;21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). These forward-looking statements are subject to the &#8220;safe harbor&#8221; created by Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act and may include, but are not limited to, statements about&#58;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the success, cost, timing and potential indications of our product development activities and clinical trials&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the timing of our planned investigational new drug application submissions to the U.S. Food and Drug Administration for our product candidates&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the timing of the initiation, enrollment and completion of planned clinical trials in the United States and foreign countries&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to obtain and maintain regulatory approval of our product candidates in any of the indications for which we plan to develop them, and any related restrictions, limitations, and&#47;or warnings in the label of an approved product candidate&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to obtain funding for our operations, including funding necessary to complete the clinical trials of any of our product candidates&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our plans to research, develop and commercialize our product candidates&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to attract and retain collaborators with development, regulatory and commercialization expertise&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the size of the markets for our product candidates, and our ability to serve those markets&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to successfully commercialize our product candidates&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the rate and degree of market acceptance of our product candidates&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to develop and maintain sales and marketing capabilities, whether alone or with potential future collaborators&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">regulatory developments in the United States and foreign countries&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to contract with and the performance of our and our collaborators&#8217; third-party suppliers and manufacturers&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to develop and successfully operate our own manufacturing facility&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the success of competing therapies that are or become available&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to attract and retain key scientific or management personnel&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing&#59;</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our use of cash and other resources, including our expected use of the proceeds from our initial public offering and any offering under this prospectus&#59; and</font></div><div style="text-indent:-27pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and our ability to operate our business without infringing on the intellectual property rights of others.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">5</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In some cases, you can identify forward-looking statements by terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;goal,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; the negative of these words and words or similar expressions intended to identify forward-looking statements. These statements reflect our views as of the date on which they were made with respect to future events and are based on assumptions and subject to risks and uncertainties. The underlying information and expectations are likely to change over time. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date the statement is made, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Given these uncertainties, you should not place undue reliance on these forward-looking statements as actual events or results may differ materially from those projected in the forward-looking statements due to various factors, including, but not limited to, those set forth under the heading &#8220;Risk Factors&#8221; in any applicable prospectus supplement, the documents incorporated by reference therein or any free writing prospectus that we authorized. These forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements contained in this prospectus, in the documents incorporated by reference herein and in any prospectus supplement by these cautionary statements. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. Before deciding to purchase our securities, you should carefully consider the risk factors discussed herein or incorporated by reference, in addition to the other information set forth in this prospectus, any accompanying prospectus supplement or free writing prospectus and in the documents incorporated by reference.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">6</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_61"></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">USE OF PROCEEDS</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Except as described in any prospectus supplement or in any related free writing prospectus that we may authorize to be provided to you, we currently intend to use the net proceeds from the sale of securities under this prospectus for general corporate purposes, including clinical trial expenses, research and development expenses, general and administrative expenses, and capital expenditures. We may also use a portion of the net proceeds to in-license, invest in or acquire businesses, assets or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions. As of the date of this prospectus, we cannot specify with certainty all of the particular uses of the net proceeds from the sale of securities under this prospectus. Accordingly, we will retain broad discretion over the use of such proceeds. Pending the use of the net proceeds from the sale of securities under this prospectus as described above, we intend to invest the net proceeds in investment-grade, interest-bearing instruments.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">7</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_64"></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">DESCRIPTION OF CAPITAL STOCK</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">General</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our authorized capital stock consists of 200,000,000 shares of common stock, $0.001 par value, and 10,000,000 shares of preferred stock, $0.001 par value. All of our authorized preferred stock is undesignated.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summary description of our capital stock is based on the provisions of our amended and restated certificate of incorporation and amended and restated bylaws and the applicable provisions of the Delaware General Corporation Law (DGCL). This information is qualified entirely by reference to the applicable provisions of our amended and restated certificate of incorporation, amended and restated bylaws and the DGCL. For information on how to obtain copies of our amended and restated certificate of incorporation and amended and restated bylaws, which are exhibits to the registration statement of which this prospectus is a part, see &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information Reference.&#8221;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Common Stock</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Voting Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Our common stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors, and does not have cumulative voting rights. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Dividends</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Subject to preferences that may be applicable to any then-outstanding preferred stock, the holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Liquidation, Dissolution or Winding Up</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  In the event of our liquidation, dissolution or&#160;winding up,&#160;holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rights and Preferences</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fully Paid and Nonassessable.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All of our outstanding shares of common stock are fully paid and nonassessable.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Preferred Stock</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to our certificate of incorporation, our board of directors has the authority, without further action by the stockholders, to issue up to&#160;10,000,000 shares of convertible preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will fix the designations, voting powers, preferences and rights of the preferred stock of each series, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. This description will include&#58;</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">8</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the title and stated value&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the number of shares we are offering&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the liquidation preference per share&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the purchase price per share&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the dividend rate per share, dividend period, payment date or dates and method of calculation for dividends&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">our right, if any, to defer payment of dividends and the maximum length of any such deferral period&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the procedures for any auction and remarketing, if any&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the provisions for a sinking fund, if any&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any listing of the preferred stock on any securities exchange or market&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">whether the preferred stock will be convertible into our common stock or other securities of ours, including warrants, and, if applicable, the conversion price, or how it will be calculated, and under what circumstances and the mechanism by which it may be adjusted, and the conversion period&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">whether the preferred stock will be exchangeable into debt securities or other securities of ours, and, if applicable, the exchange price, or how it will be calculated, and under what circumstances it may be adjusted, and the exchange period&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">voting rights, if any&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">preemptive rights, if any&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">restrictions on transfer, sale or other assignment, if any&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">whether interests in the preferred stock will be represented by depositary shares&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">a discussion of any material or special U.S. federal income tax considerations applicable to the preferred stock&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any limitations on issuances of any class or series of preferred stock ranking senior to or on parity with the series of preferred stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up our affairs&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any other specific terms, rights, preferences, privileges, qualifications or limitations of, or restrictions on the preferred stock.</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we issue shares of preferred stock under this prospectus, the shares will be fully-paid and non-assessable.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The DGCL provides that the holders of preferred stock will have the right to vote separately as a class (or, in some cases, as a series) on an amendment to our certificate of incorporation if the amendment would change the par value or, unless the certificate of incorporation provided otherwise, the number of authorized shares of the class or change the powers, preferences or special rights of the class or series so as to adversely affect the class or series, as the case may be. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have no current plans to issue any shares of preferred stock.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Anti-Takeover Effects of Provisions of Our Amended and Restated Certificate of Incorporation, Our Bylaws and Delaware Law</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Delaware Anti-Takeover Law</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">9</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to Section 203 of the DGCL, which generally prohibits a public Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless&#58;</font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of determining the number of shares outstanding (1) shares owned by persons who are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">on or subsequent to the consummation of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2&#47;3% of the outstanding voting stock which is not owned by the interested stockholder.</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Section 203 of the DGCL defines a business combination to include&#58;</font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any merger or consolidation involving the corporation and the interested stockholder&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In general, Section 203 of the DGCL defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provisions of our amended and restated certificate of incorporation and amended and restated bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our amended and restated certificate of incorporation and amended and restated bylaws&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change in our control)&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">provide that the authorized number of directors may be changed only by resolution of the board of directors&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">provide that the board of directors or any individual director may only be removed with cause and the affirmative vote of the holders of at least 66-2&#47;3% of the voting power of all of our then outstanding common stock&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">divide our board of directors into three classes&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice&#59;</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">10</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose)&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">provide that to the fullest extent permitted by law the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to us or our stockholders, (iii) any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or bylaws, and (iv) any action asserting a claim against us governed by the internal affairs doctrine. The provision would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Transfer Agent and Registrar</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The transfer agent and registrar for our common stock is American Stock Transfer &#38; Trust Company, LLC. The transfer agent and registrar&#8217;s address is 6201 15th Avenue, Brooklyn, NY 11219. The transfer agent for any series of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement for that series.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Listing on the Nasdaq Global Select Market</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;ALLO.&#8221;</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">11</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_67"></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">DESCRIPTION OF DEBT SECURITIES</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will issue the debt securities under the indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended (the Trust Indenture Act). We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summary of material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">General</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The indenture does not limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against changes in our operations, financial condition or transactions involving us.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may issue the debt securities issued under the indenture as &#8220;discount securities,&#8221; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#8220;original issue discount,&#8221; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable prospectus supplement.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including&#58;</font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the title of the series of debt securities&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any limit upon the aggregate principal amount that may be issued&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the maturity date or dates&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the form of the debt securities of the series&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the applicability of any guarantees&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be determined&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">our right, if any, to defer payment of interest and the maximum length of any such deferral period&#59;</font></td></tr></table></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">12</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#8217;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities&#59; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities&#59; and the depositary for such global security or securities&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&#8217; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">additions to or changes in the provisions relating to satisfaction and discharge of the indenture&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">whether interest will be payable in cash or additional debt securities at our or the holders&#8217; option and the terms and conditions upon which the election may be made&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any, and principal amounts of the debt securities of the series to any holder that is not a &#8220;United States person&#8221; for federal tax purposes&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any restrictions on transfer, sale or assignment of the debt securities of the series&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations.</font></td></tr></table></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Conversion or Exchange Rights</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidation, Merger or Sale</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">13</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Events of Default under the Indenture</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect to any series of debt securities that we may issue&#58;</font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.220%;"><tr><td style="width:1.0%;"></td><td style="width:1.752%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.752%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.496%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of 90 days&#59; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series&#59; provided, however, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">if specified events of bankruptcy, insolvency or reorganization occur.</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that&#58;</font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the direction so given by the holder is not in conflict with any law or the applicable indenture&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if&#58;</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">14</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the holder has given written notice to the trustee of a continuing event of default with respect to that series&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer.</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Modification of Indenture&#59; Waiver</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We and the trustee may change an indenture without the consent of any holders with respect to specific matters&#58;</font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">to comply with the provisions described above under &#8220;Description of Debt Securities-Consolidation, Merger or Sale&#59;&#8221;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">to provide for uncertificated debt securities in addition to or in place of certificated debt securities&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under &#8220;Description of Debt Securities-General&#8221; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee&#59; or</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act.</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected&#58;</font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">extending the fixed maturity of any debt securities of any series&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities&#59; or</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver.</font></td></tr></table></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Discharge</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">15</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to&#58;</font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.764%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.764%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.472%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">provide for payment&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">register the transfer or exchange of debt securities of the series&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">replace stolen, lost or mutilated debt securities of the series&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">pay principal of and premium and interest on any debt securities of the series&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">maintain paying agencies&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">hold monies for payment in trust&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">recover excess money held by the trustee&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">compensate and indemnify the trustee&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">appoint any successor trustee.</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Form, Exchange and Transfer</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company (DTC), or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we elect to redeem the debt securities of any series, we will not be required to&#58;</font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing&#59; or</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">register the transfer of or exchange of any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.</font></td></tr></table></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">16</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Information Concerning the Trustee</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Payment and Paying Agents</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Governing Law</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The indenture and the debt securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">17</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_70"></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">DESCRIPTION OF WARRANTS</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be issued independently or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have filed forms of the warrant agreements as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, if any, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to the particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplements related to the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and the complete warrant agreements and warrant certificates that contain the terms of the warrants.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">General</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will describe in the applicable prospectus supplement the terms relating to a series of warrants being offered, including&#58; </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">18</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the title of such securities&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the offering price or prices and aggregate number of warrants offered&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the currency or currencies for which the warrants may be purchased&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">if applicable, the date on and after which the warrants and the related securities will be separately transferable&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">if applicable, the minimum or maximum amount of such warrants which may be exercised at any one time&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at which, and currency in which, this principal amount of debt securities may be purchased upon such exercise&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which, and the currency in which, these shares may be purchased upon such exercise&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the terms of any rights to redeem or call the warrants&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the terms of any rights to force the exercise of the warrants&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the dates on which the right to exercise the warrants will commence and expire&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the manner in which the warrant agreements and warrants may be modified&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">a discussion of any material or special U.S. federal income tax consequences of holding or exercising the warrants&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the terms of the securities issuable upon exercise of the warrants&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</font></td></tr></table></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including&#58;</font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture&#59; or</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.</font></td></tr></table></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercise of Warrants</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent in connection with the exercise of the warrant.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">19</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Governing Law</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless we provide otherwise in the applicable prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the warrants or warrant agreements, will be governed by and construed in accordance with the laws of the State of New York.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Enforceability of Rights by Holders of Warrants</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">20</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_73"></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LEGAL OWNERSHIP OF SECURITIES</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee or depositary maintain for this purpose as the &#8220;holders&#8221; of those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names as &#8220;indirect holders&#8221; of those securities. As we discuss below, indirect holders are not legal holders and investors in securities issued in book-entry form or in street name will be indirect holders.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Book-Entry Holders</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#8217;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Only the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers&#59; they are not obligated to do so under the terms of the securities.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result, investors in a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#8217;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Street Name Holders</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A global security may be terminated in certain situations as described under &#8220;-Special Situations When a Global Security Will Be Terminated,&#8221; or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &#8220;street name.&#8221; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and&#160;the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Legal Holders</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For example, once we make a payment or give a notice to the legal holder, we have no further responsibility for the payment or notice even if that legal holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the legal holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">21</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Special Considerations for Indirect Holders</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are represented by one or more global securities or in street name, you should check with your own institution to find out&#58;</font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.220%;"><tr><td style="width:1.0%;"></td><td style="width:1.752%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.752%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.496%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">how it handles securities payments and notices&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">whether it imposes fees or charges&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">how it would handle a request for the holders&#8217; consent, if ever required&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">if the securities are in book-entry form, how the depositary&#8217;s rules and procedures will affect these matters.</font></td></tr></table></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Global Securities</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, the DTC will be the depositary for all securities issued in book-entry form.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under &#8220;-Special Situations When a Global Security Will Be Terminated.&#8221; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Special Considerations for Global Securities</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As an indirect holder, an investor&#8217;s rights relating to a global security will be governed by the account rules of the investor&#8217;s financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If securities are issued only as global securities, an investor should be aware of the following&#58;</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">22</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">an investor may not be able to pledge his or her interest in the global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the depositary&#8217;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#8217;s interest in the global security&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">we and any applicable trustee have no responsibility for any aspect of the depositary&#8217;s actions or for its records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">financial institutions that participate in the depositary&#8217;s book-entry system, and through which an investor holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities.</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Special Situations When a Global Security Will Be Terminated</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations occur&#58;</font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">if we notify any applicable trustee that we wish to terminate that global security&#59; or</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived.</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">23</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_76"></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PLAN OF DISTRIBUTION</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions&#58;</font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">at a fixed price or prices, which may be changed&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">at market prices prevailing at the time of sale&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">at prices related to such prevailing market prices&#59; or</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">at negotiated prices.</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may also sell equity securities covered by this registration statement in an &#8220;at the market offering&#8221; as defined in Rule 415 under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either&#58;</font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.922%;"><tr><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">on or through the facilities of the Nasdaq Global Select Market or any other securities exchange or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale&#59; and&#47;or</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">to or through a market maker other than on the Nasdaq Global Select Market or such other securities exchanges or quotation or trading services.</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Such &#8220;at the market offerings&#8221;, if any, may be conducted by underwriters acting as principal or agent.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable&#58;</font></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.327%;"><tr><td style="width:1.0%;"></td><td style="width:1.789%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.789%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.422%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the name or names of any underwriters, dealers or agents, if any&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the purchase price of the securities and the proceeds we will receive from the sale&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any over-allotment options under which underwriters may purchase additional securities from us&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217; compensation&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any public offering price&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any discounts or concessions allowed or reallowed or paid to dealers&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any securities exchange or market on which the securities may be listed.</font></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">24</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may provide agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other than common stock, all securities we offer will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. These transactions may be effected on any exchange or over-the-counter market or otherwise.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any underwriters who are qualified market makers on the Nasdaq Global Select Market may engage in passive market making transactions in the securities on the Nasdaq Global Select Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security&#59; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">25</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_79"></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LEGAL MATTERS</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the validity of the securities offered by this prospectus, and any supplement thereto, will be passed upon by Cooley LLP. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.</font></div><div><font><br></font></div><div id="ieed28d9304df4001833e3a91896e00cb_82"></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXPERTS</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ernst &#38; Young LLP, independent registered public accounting firm, has audited our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst &#38; Young LLP's report, given on their authority as experts in accounting and auditing.</font></div><div><font><br></font></div><div id="ieed28d9304df4001833e3a91896e00cb_85"></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">WHERE YOU CAN FIND MORE INFORMATION</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including Allogene. The address of the SEC website is www.sec.gov.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We maintain a website at www.allogene.com. Information contained in or accessible through our website does not constitute a part of this prospectus.</font></div><div><font><br></font></div><div id="ieed28d9304df4001833e3a91896e00cb_88"></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The SEC allows us to &#8220;incorporate by reference&#8221; information that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We also incorporate by reference into this prospectus the documents listed below and any future filings made by us with the SEC (other than Current Reports or portions thereof furnished under Item&#160;2.02 or Item&#160;7.01 of&#160;Form&#160;8-K&#160;and&#160;exhibits filed on such form that are related to such items and other portions of documents that are furnished, but not filed, pursuant to applicable rules promulgated by the SEC) that are filed by us with the SEC pursuant to Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act&#160;after the filing and concurrent effectiveness of the registration statement but prior to the termination of all offerings covered by this prospectus&#58;</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">26</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.220%;"><tr><td style="width:1.0%;"></td><td style="width:1.752%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.752%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.496%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">our Annual Report on </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1737287/000156459019006991/allo-10k_20181231.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Form 10-K</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for the fiscal year ended December 31, 2018, filed with the SEC on March&#160;8, 2019&#59;</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December 31, 2018 from our Definitive Proxy Statement on </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1737287/000119312519115774/d743180ddef14a.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule 14A</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, filed with the SEC on April 24, 2019&#59;</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2019, June 30, 2019 and September 30, 2019, filed with the SEC on </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1737287/000156459019016480/allo-10q_20190331.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">May 7, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1737287/000173728719000008/allo-20190630x10q.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">August 7, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1737287/000173728719000020/allo-20190930x10qq319.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">November 5, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, respectively&#59;</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Current Reports on Form 8-K, filed with the SEC on </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1737287/000119312519044774/d705652d8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">February 20, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1737287/000119312519102909/d695225d8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">April 10, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1737287/000119312519169316/d761662d8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">June 10, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; and</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the description of our common stock, which is registered under Section 12 of the Exchange Act, in our registration statement on </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518294785/d616804d8a12b.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Form 8-A</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, filed with the SEC on October 5, 2018, including all amendments or reports filed for the purpose of updating such description.</font></div></td></tr></table></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits which are specifically incorporated by reference into such documents. You should direct any requests for documents by writing us at 210 East Grand Avenue, South San Francisco, California 94080, or by telephoning us at (650) 457-2700.</font></div><div style="text-indent:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">27</font></div></div></div><div id="ieed28d9304df4001833e3a91896e00cb_91"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%;">11,702,128 Shares</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><img alt="image_11.jpg" src="image_11.jpg" style="height:78px;width:338px;"></div><div style="text-align:center;margin-top:18pt;margin-bottom:66pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%;">Common Stock </font></div><div style="text-align:center;margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">PROSPECTUS SUPPLEMENT </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Joint Lead Book-Running Managers </font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">Goldman Sachs &#38; Co. LLC </font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">Jefferies</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">Cowen </font></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Book-Running Manager</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">Piper Sandler</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Co-Lead Managers</font></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">Canaccord Genuity</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">William Blair</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">Oppenheimer &#38; Co.</font></div><div style="text-align:center;margin-top:30pt;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:2pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  P ,P# 2(  A$! Q$!_\0
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M[Z7_ .AWU0_\%+#_ ,;^OV>?^O;0O_3A?5)^WC,L/_!Q/\"6;[OD:2OXF2^
M_G6U/['_ %[9PXQ_O,1_V%4_RB4_^"H!US_@H7_P5E\"_LTMJEWH_@?P^(;W
M4!:N"TTKVYNKBX*GY3(D 6&(L&\LO(P!W$5]H>*O^"-O[./B;X3R>$5^&>BZ
M7;^08H=3L%,>K6[8P)1='=(S@\_O"RD]5()%?'G_  5N\#^,/V%/^"B'@O\
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MPA^%\]QI%E8QB=EG,.P/$HB#,K7$^6DD7#-'"B[AM3'M/A^5HO\ @YYO]O\
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@]/Q^XYL3_9<:3A@:/LVY75E9*-MG[SN[];*^NU[+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_02.jpg
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MCZ=KFK)ZX*;/_:%PJN'">@4\P_&[\7N!I8@N^ON?8?O;\2K9LH5G*I@;V3\
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M?W!5LL6/"J\:M%.XY/<OQQ\K*)9FS .%5PT@M[$"@M.!=_)5GN+C>=Z0/?N
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M=E*!>PN)9.BY\/-:".:.CP@#/^\VE$9P$DJZG[MM- PDBS^-<+XM%WAN4KB
MHZO6T-I2384$PL(ZN_5 (I@+I_D/TOY''>4;F7/<Q:,/;!2-_+R%"]#SVYWW
MO%2O-6J("[M6O@%7#!DZ6T5X],E3N,!8+/TZ7)$H7.U1++N)(TY^8#2>_B7?
M)WMX2TH]D CX+D@\-@2V6'BW6?!SONSNVJ/:77>+":#DRF?0?URM&;U-1W*H
MLT6BP(1MOZ\(IX:% U!!?(,Z@#_=9]TZ13CYP*-(]507C ,4"OMHAA&Z\&%I
M9H-&ZM+GEQBEUPNG]N%P:SV@D)V"YBTH@4(/ KWDH62R[KZ8G0E<N UZTSL5
M4'"H,53@9Z+0QTAOU0J5T]1"V=YT33UEM5#])^[A[]C5P'N*4=Z$^YT1V$Q.
MO=09CLV:;W:X5LG8]D6P+PB$^Z&H[HY3PYC\4#3)&]B&8LD+B2;9@[!5B"HV
M/!]-?>OTCM6[XTP')_S8\N1_XPJ0_U>&HBD>$1Q<KA\YM#S9-1CK[OM;^B74
MU^E^UU L]<'SN[MG;S-/-=?S>2>7KEKU+&=_K@,4)C6]7,@ [+B3&^]QT?+6
M(>RXDX*'8$5A^B@?OFMPBO)B2HRE3](]QN5Q3P5[_T@LQ?>;8^G'OD?YB'ML
M(J,"_0/NL3]H)KQ_7]%Y\;B**PH2^Y+840 ;S<C_.>*Q=4 U$;<^V%L;R_VX
MQ_*;T43RG72[FUKJXR')()!)XG:G!,G0=U,K=!PVB FG4'@Y]PKJIS@;N@9B
MJ9,V+>OB0X/&HMUL?)4*ZD^WZ2]V\^5J8@HG/#CZ&L]DC%NXR_4/X3H6TZ>I
M\MQ"7+T>%6=LV<$MCP"&HF8-E4>'!13#G/#*77"TN)7864$U:-<_FN[I!.I8
MY,5M1T &NV<<2>RD4(_-U[5G(2$A(2$A(2$A(2$A(2$A(2$AL8@!P\[M3A'A
M&#=L5U!RQ?K'&DI(2.P8C,3T!S%-B,,TAJ*KZIHAE)"0V [8DD@_>%GWBNE!
M<2B*%YJU'C:HF\X2*L7>MRM&U35\[F BH5^.W:/#\?2[A).$A$2[T*H;SQ&W
M/F#5,Y;-#05.(.(EXH8UK95Z?;M4@^?14YB[$ ZD&*9O+:5SAAE):]Z_[X62
M+?4IN5)9/$I(2-2#5CVAK>/!@L"":'27T6UFBNELA&*VX'T<\V OJ1UHN?(;
MM%[[#)^Y@+=N".,;L*D@G%U$C,IA[(^],T1*UN*%XQ(2<P:D*?;U8@.9<.K
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M91\GW==E%&+,J[T,.N(Q9P6K .-Q_4N3<?T(X<282.B/..] FH\M6[8'W'$
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M?B2>? O<QHE^[-G]YN#2KA7N&5H 5;S=*.P[\,Y85X]K=66BJVNY-_Y?'W
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MBF']0BVOOU_)5R_1C')4^,P[E*R94(J52_$M-6?^I*._GX^!EI"0D)"0>-I
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MUA9"M]R,1/4W3"7TLRF>OY# O9/B'QN.I]QY*<J\([E2APC"1L3OY$L?$-%
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M9ZU[N1$+>5\C=R6_L%HC"?\?HD&J^3Z1*.^ZAX10PWY*_7<W3$=RULR1G0L
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M7K#4J(8RI):U#N+&D\J"350:UI3PFA<H&>N58* PQ@(A?=2H+:AQ@5"P=M7
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-+P    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_11.jpg
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MRY(1LX&?RKJ&-H!H:)*I\YHBZNHEKLM5:E]5NI[3E<!G&A923S(([Q!\^4H
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M76_@"UYD*$__18WODLN6$Y"Y!#$7<=4R-#JEQ\2P++1_\2#=L&W0TU!/1Q.
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MPKBD057@JP+?C0(^#P(. L"B_280:TK7\+<H@"H37SY>-6G!X*W]JE)J&'P
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M%)?TSM*?CM+'<99/\-HNM08US)@K)VM,UQ?X6"!;E<2T%:E21QJ*!H:]+SA
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MN4N.)P?>7!A:@_X V+\:ZOX)\$44>I96E#53RA-88RQ%3F!#C@A\UKE+'C8
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M^L6\!FYV">/BIMNG7/MM>XF"M'F9<$Z'M;37\LTDZFFKOP'@L[L]&$("_D>
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MHL8*0V.%$9^+')'AT1L;J[A6C"5YM+Q)NCI>2:527",+.$:*.)4>+%;-X:9
M#0463:G!,"%7JXAAM='PA4Z=9-8CE3S>P$7#W=#H\31'FD56>'%U$[/AV66+
M4-!+Z&B7[QR?OV+!JV\7]QLR1YKYT]Q/ZX5:CU!_)?@0 Y^OUEUV:P?#3QOQ
M\J)> [YX:OC\04.6#'EV5UZ!<.>>&X?KPC:O9^6].Q-N7/WDX?V]X> YXGF6
M8%%UHAUZ[[90<D^X>D7X]8)P\H1041X,!CT>3_K*K_ H:[49R?51[ 2D*4C5
M&I/5>D"]!/"#X$B$I\(H$25_DS<>JZO'M[8L()R])9R_(UPX+]R^90]>#0CW
MZSVE8=S.AA\*G&,[[SOF7+H]\_RU_=5U-[%'$?:75E>M^'K<H.>W]W]NS^"_
M+!G\RIS>SZU0F3T_GL$;U>YJ&!CH.+-C\^(L5>Z(-SX9]H_=JOPZEP>PSQ-Z
M?!1.T(.]DB<$/H(ZXH2\+;?+^Z4IVIMS$A6:1E*J#03U 'RLH:<Q[ZL:=Z2=
MNP'XP&JP7)A'?-% P!X,.AX2P'IA_-P6&6RB=2I264DFQ=18+H6%^_7!GS"9
MN89T'CPA\,60PJX(?(?_SX#/66MWXI[I<&^9L?TH-<H;AVQY408K8'23L9(W
M9\TO)UNEIJ;JT8W[KP,?H%X](;5HOUS1'(*CK P$+@,F7=EBV*)!V=2N4H??
MXX./'B1%'OC)#V;,1 HJ@;-$4^88G;D-96FAU#^O8XYY?&+]-%1+U'<\GC\!
M/CN1,@J[ X3G"3^)0X-RP3=FU=+V&BG2JD7@:T3KFS.6'H531.#SDBY' #Z'
MSW7:[WI>JVBJ9U'&V"C2(]'"DIM$Z]M+-:TRY/&<#+ /T9(H3AYM8Q"OQ&DO
M3HT,+#8.=@073_-@R5ILJ1IMBEK=3$4#]B5D4XD272QEQ,!'&^(M^;$*.D:F
M&R0SO5L\YYZ=Q %_ 'Q(JFFFMW;@N%2I=*A.?M!=@U,LWL"3 A_\XXV*ND&V
M_+8R%5:[R1F'I"QB\WJG,=F?K@H0U42_!XLFX-$E0FAKB3!0FM],;4G(8K#_
MBP6F=$AO:LOGH/?3>ND+VBKX9 T3*U,C6HO,X ]AB]/P8+%:'5B,3@,6S^MB
M&#72RE,L/))F)ABY.+C#&B52LLGZ'(QZ:FWJQ"(DR8AGJ6<6+T NUTU,Z-NS
M;^&PYRZT>.94RL C'4:<Z/9:[=DS<&&_"JXK>!\[;YP]MK;9X/W]WMK=NOMO
M0_ZRIG/7[_L-6/[7EX0=W^/AE6"X*((3GD0GA,@;U$-\%B@GE5^/CV0S27+:
M1;*S$+$?\PN=\HN3X6CB\)S)&)L-POMXVA*C,28H^22U(0;@0*Z.5L@2M.JG
M9>KO;]X3L[QBINRV$+Z*TW6!6H'4 NPD&'1X(\-V EYO96FUX "K#]ROL%\]
M\H%D:>]G#G=MN[]#BX.]G]K5N<_2X6\X9J\@,F4.(503LM\3[MW<K);MZC_\
MNTY]#G<<?+3KT(US/\,%!HB:G!#PAVK#'M(#VT!>%K&0B(!&$KT-I.9(\0/S
M.C"=V.L) $S>#N'@[OV%*UI)5 C.><:0K-$FJ;5QV=)F%/W^YU\N*BG?+0A;
M_,(/[N!63W"[)[C#&]SI"^WRAW<%L/T8"![P!_:&A.^J[/3N0WWR)B"E#LM#
MZ9A8WI"DE#=G=*_EVGX.X):[Q_P^;&0B*01=X4A%+$#&Q(2$K*5K.V9HL<_(
M&! #L8D)3DY$J;:=/E/QB,#L;P ^G_!E;4T;C3I>"XL/UK25E#+AURG+_(4E
MY)B!*)NTH&,1V<L.3^\LOGLZC14]3>,P.=9D:J90O3IG;B717R!:G)%!T6*H
M&P&^QS,(CY'#Q=UFQV0=G)[/7_=UDD(3E2&)*1B/72U#,:)L0U2J3;?O8*7)
M<)W; [?<<5007BK*C[$5(17;R%  %I^E:J;1/ZV17HV,4A/+>6*O3.1(B\!N
MPSD&YB"J0I&(UXD#7I']IUFWM8?*B!1</ /^.X_4;&,MTZV@^)ZCMC(8&8$1
M"H9]/O_AFMKGE*I8AHL'-X0'%YA-XL<E,/FI[RIZJ_.1A4%&V/D4,C(XS0_&
M$^-$XX@QQ&ALM DLBB*F,X(U_*0:7,583AG#*KI+LOX^9>)=3Y#,0<1>E[AT
M;V)9JME1K"Z*I:,TYEB=+4YCB%*P _3\-H_[/P>V_Y4_L#ON57M:%.<@1A6G
M-"13N&X319OC5?)7EBVN<44FO(F=.<&0[ZLR5Q^^()9B$UD#EK"SF3 *T[I$
M)9.@H)O+N80T5<L\\ P8Q%#(I(_66L$09<;&Z+'AC &')])@(W<, GQL)K!&
M&DLBEK,UPKD>:QV'5$R\BG]N_DH$J&>W7W7,6SBQ6X^K[5^XU>5E0+V#;9^_
M=^204%/]J^#$P.>HN'+JR)9.+QX8\/:)WD/WMNFQH7??'4.&YG5K+VQ<)U26
M"K>OBVRIR#(E)<E0!028 7$$7.0>NKU!1[V8,1.!KP,<"%F**),ERF2-MEF1
M2HF%QE1Z0+T4RI0 )QO%)NFT*8RN7[ID_;7;0=R+*[A=?KAO-P4\A;(6UZV=
M6/-,K(/B.4(!9V4E5E,-@*-D+\$YXO('E;]^_Y>_KQWZRB\#>ASMV?'$X.<.
M]!@T9^"+ERT3 ^"-NNMQ0YJS1#A]=/&[?_NV8^^#0U\ZVV_$WE9]5D^;*I27
MXNY/G]-%6M]$O_))@4_ $Z?P,;#[\LU!ML*F:9($O04>)P!?4X9KHM$ERI0=
M&/W3XR</*YK4@S,-RRL"&YX[CE@AV+#< K!G#$8P^.;S!>.[&'(3,Q5(BKO'
MB$XGFZ)6)LJES]#4G*-'JL4AG(\!7\,09N'_'^#SX6&,PBU?N%<FUR,=%FX.
M,A0@O1Y9S"U4FA$S9U6*1"7A=W?BOPY\XF>!553P];?@. /VX8P2:T1ZP-;\
MIQ2*G5A(NP: S^.%#X&ETEX9/PXW,%%Z7%GF\Q(EVB8J;B@EO]0PJ%!X;*[E
MGP!?K7@IX8@7+[+_I%]LZ*8T /#%T3:1+M-8RW8O''_?::\19SG#$L'#U,+'
MZIU_H>AH'=,(7!MK(3+DQ#/YB6Q!T_=5+4=2R,:C'#W*,6(S&R+ 9X#M32P"
M:L1'$^&/,1/I5M%,8)&?A!>Q<@!\2)O=8>RH-R<6WW3Z:O_G@"]1K7AU^9):
M-]'>#@0:@,_[76VHB]H,P)> 44R+@0]03,^WTN>T8"U-I$Q*%A4/CU6!40]\
MWBB-!0QI3=AHDAQG&6S@WX$9.&)Z8D9L"GT<FX?9J3IS(V,N4M+)E/FEI:L1
MIA(&/95[]X][]_T53[\RI\<SR_J_O/&ECUSG?Q6J:^OP%&6/4'7_X:DC&X:_
MOKCKH(.#7US7HNN:9YY=_^)+N2.>%RZ<%;=]&0ELK_GQ&2Y23+V8NQ^J"?CO
MU=;@B,WO%:HJA,IRG*QWU->%A0<.]XO%4YJ,RHB#?0M;"#X#HT]4F)-5UGB-
M*59EP <:?!BS"ID4?6C%-Y7W!4)H$VK<V,I*!*>]#NM".X@@2>!&T"G2XG&'
M634692OQUY.\AJ?NSHT?7TK_IO=K/W3N^'V']M_W'OY=MZ=FC'CGVJ>?^S'-
M-B02(X6'M[ZTZ6=T[[=PT/#5?89],_"%'2N6"V5EV"L,>&$GVP/N2);G\>B1
MJ-I$@._QL#<R$1EBI3#I)<,<+N/BSY,DROA,63R$?BH*KUU _-Q<?$:Q\,P,
M,7I '[8118-%:2EBVD9:+=)JP%JPX$IH$]4Z\/]C=,9HRH#)$$:BQ\T8$P"Y
MLN2=Y=HWIWWZ:P"O[ @+F B=B_0:D8\C A^>&QL2,I>M[9"IQ91 /%SB"8$/
M?EX? 3[S_(68-@Q'H"?H(:YE!5D5O;*8[ND4OD[>1DBMIC8R];/%DVM$EA;>
MB6%QC"$9P>V+E- ?*QPU[,'?OR=*]H.S9EZ^*EFB;:DU8!> R\&$57WAP&SI
M3TXW$=6N#^$"O>NB(+P[:1*&:8 &^#'6%JOAP)[2RD_@4:TX@Q(A+46 #]>P
MZHGY'GOBD39$C^>1$'\Y21>\M_"+]DH.J?@HVM(('@JE!^#K.6[B0Q>NN<%J
M\/F\XIR-,Q[O6P9#M%J#9 I,HM9;D=H83>>TS.(ZJFP]TN1]LM3]LZF^69K>
M:<J>8^2]QBIZIZMZIBG NF?(P;IFRL Z9TG!VDI48)VR1%.#M9&JP!K+LIO(
M)>UDF1V5DF<EV9J9,\OK?9[_.>!+TJA>^WQ9G1??S'"P ?B"WI]\0N\LJJF&
MP=W3@.9ZK-"!*^,?97?D\SNE:;I+V,Y9BB[9RJX,U5HNZ9I!8<O4@'7)5(!U
MS9*!=2/6/5,!UC-#A2U= ]9EC*R?G.XBUW0&TU MLR0#M4S&_,6HIK8<*[L\
M*-T^==KWKX_\K/O0#2]]6&*;(=3:!8>S5G!AX(. _\&-W[+IY3V>WM5[Z(Z>
M3W_YU#.?#WQJHXD7KEYRU];X''; FG,5=5LOW#Q\K^I./< E[F:M][DB;"-
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M #ZK&0[^_R[@4\;#K\@D&'JD2U:\^@!\'AL^L$B'$3C5_6C3V^=M11Q*+JN
M#5(I7M^<JBIEW83XBK^.[IJ0NN/VDSO60$F\P>0V&%W8><-3D6>VFHDHFILX
M,]B<7GGNQC!50G!H6&VQA-+(JZ4F -&=QZD5$Q\LD:TY?@IO^V+&9R6P!>1Z
M(DY%NJVAQ[3W8D')YQQA_2A!B#:1$BD^4\?@G59-I B1JEKSI/P_=]PL,A>2
MF /9HG\_;$1V 4_:^9S\[V=-;3AQ="5.1#4AMX(<.%C!RA1*FHB!#SM 07QA
MLRG3_@7P'<U^.FSFHEJ_AX;(5+65T?@6*FE4S?#%_#)J@#8V[=C)TV_>%!'@
MLWS %0]C<?IL7C:TQ9B]&/5N6PRSC^P?+!>W&_/;F*FI6R]=?FBS!6IL0;G>
MS:XB-^2F'?]IP&=F@(L.1#23I;5:6^'74;434RLJ--!!4"*O*Q17BXAJ-WY"
MS.;-3TI+=6SY41G)G'@ 'J?983?:V!29"<1#2T3S%_8*#>_)$W;G\.8<RKA4
M:C(0CX<I2QDQ#$/=H'W*#9LG[]A\L13TB6V0P8<MB&]@T][,.N/#6HH5U<,Y
MM3B"KWZ+&#UC*7Z*!=A TQDA9%BD1P4Z9++"\/E<9O-3FR77[V4Y1,5VH,@!
M49GV%5^\_6?2]'G]AT_J.B!MV$^[E3%/;UT#BA]R@]"&Q8+R\AZJ$W<-^V5_
MJ]8'VK3=VK3=L>[]+VKBT:%C<%:!LAKP;]&[@B/+TE>-#$OK,VQ2EV\VCAQ_
M<_%F5$@3+554Q'B+H-,#R=5ZF%RP2$%"$@17<E\A6R%REJ!"$S$JT,'])QO^
M/K;IA#!*-('BCZT3\>MO:Q?8&)"6Q+?OUUGP)!<5Z":=.!I[<,_>K*PB%G"\
MI$$4+ AO&06C#/@"@,AX@5T+6\Y(HH0S+MWJ*--6CHF%;+U&0VFBJT4(:W&E
MW2+5>Y_K8$>R\5?\ _Z3[>;E).J?( #*,I%(@($-9[/KD0WS$^E'-B& G;M7
M5O.@R:DM>9S/./QZ>-WPI)0BIHI8$:*(CME[^.[[ BR[,R#NY 6^-]XY8S=N
M^CR*6T&B @OHDX&/T&CD4HQ]PH5+7K# !VE:O+H<I# ?^#2&8@/>ZDF;US?D
MRVN%\KZ(3PKB"JGHZ."X.+""!:+Z//FX+7L.YQJ>E[5P9%WXEZ0N[0V) YXH
M=L5L.=Q2FU(ME!\4J\768G!R#"6(K"44?J%2-1XY7K1Z4XG1Z"DK/',3*1O&
M%_ !_80,H?/[4@YF-!DUKKDZJ7J8@)+$A\1-KRB+I?C*ZB)%58%LP(RYL^\^
M?$J^-X?\^92TCGU)K&9LB)VVH,1S%[O&)]64">O@B>)P*BD4E>2)%%]349P4
M+$RH+-$&"]7X\II-GUYH V_.3PJDV)7,2IDZR'DP_="9KA'2ST6*)JJ8("GV
M!H151;$5..KJ$9(FRJ112])G7\VZ;+:_+!.>8PGA;(BID$S+O'O/?ERRJK9
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MW#1PP*GZ7]YIW_5,S_;;&M=.'OUS\:53R&Q")B- @,U=9JF1W) #5@4-99C
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M"4544CP(WN&[TRA:<:(R+.;WZQDQ 1)5H*^;^T-Z@?WW@*@7N3W\PULSJI>
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M.PM/R^LBR\1U&QMS>)241RE%E @;5E/KRV.J<J6_)L??M%NL?JO>K:>ADBO
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MHUER.%XD]WW0C1O?N(%T,?=Y'5Z\!#X1^*"JQ ,354CLS7P?K/RL]TXW ;X
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M\"6,R4WPS.RW6Z' GK'"H&TD*P@%E3Z7G6AGX>&TZ_SX<NRD)K7 A(QNDJ4
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M-3:T26S2Z&6+=A7E0_K28KJ9/&UZC_Y_=&ZW<W#_C5UZS:K?9-&O8]#M!R2
M!=K"&XZ>K#MV3#,^KXJ$4T7,J39J](^+EWA</D)!\.0R5B+;C0UCV_N!4<_C
MQV<*OGDF4$+XB:__ [[_7<"'=T.NU=9C_)AO0L>/F9.6EK'_?''1VS*V[_L@
M%MXK9@]M<+O8 @:,>D<>/1RY:$Z#L;]1$6&-XF,IJ#56!XFBJR@2JH\.ZYDR
M?=^K-P\1U*7C3W":C#LW;TH=-E+9:]".+C_M[#IB1<?!:[O_(/YQV(&E"\PY
MS_$6>[AZD_:;;Z^E_XF!+V#MFIQ[%ZZ(_W:DX]P]#'P^;,O<?Y$V<N*<QM]L
M[S=F<K]AD_H.7=KV;QM[C3Z^<C4JT6/4H^\]V/)SV.(^/RQLUW]5C^_WM1N^
ML]70/3U&Z>.6H]Q"C'T8^(K<Q +RN!YLVYPT8KAZZ.#+JU8"ZEG-,+$T1GJG
M_MGCI-]^5G__W8)F?3;V_'EMAV'I;08?&B=%.TZ"LU]L<I^].F/X;S-;]OES
MX.\;6PU9VVS@EHX_K&\]Y%#F+M#O=3NW+9B7_,TPW8X,P#LO] #"V/=HU?;8
MWG\[M'$C!CZ3QS)OY8+$GWZ:.NKW%2T'+&S<*WGP3]H^W\W[)31[Y68,?":_
MY9(J;4'O$>_.GD78RG26@F.>_?QL\M2E T?,Z?7=H=YCCPT,^Z/'B&7=AA_<
MN!892Y&U% /<C<29<_O\;6O7[T\,"YLT871HSZXKTU*9PAR&=KA=T,_$9'=0
MY?<3^Y398"&V*4M]>KVKD$8V;$5CP_LE$04CB7AOCIM)7KKB"ZFD;6)";9&B
M@4+;)THU?O("C$DY>!&:\O7/LG:U[9K1<\"]]GVN->MZI$NOX]W[S1T\R+IG
M-YY<O\?] J%5ERY+5Z\/G[]DQLHU)[/N,?C>X%@SXV'W63'PO$3NBX5O9F[?
M*5^X6+ML^>J3I^Z\?0G,,H,#7;M[MN,/YSO_^+!]QP=MVV<U[/"L5:]5/0:6
MS%SL=T(1.+:/TS9OK2;EMIJ63"G"J>DQC>-B6Z0DFXTF'TF#.$E&W @G.FAX
M.)'?XJ,+:9N9<$3P8>"T6_\-URG@$7[,J0R(E;[W_#[YQ5YY("913B#SGWQF
M^6OP?V24?^<_OC^04?"\'X%O*._"_P6!"6WE'UQCELQ2!KT?OO!]2M;S 6'^
M?O8^P!OZZ/4'J-&L<,,GOEY;H:M4;W5T5[&TEE10E1_9<E+RP/05B2?.S;MU
M[\C;DBP:^#TO22#[.D+;\DK3+EP?_L?*UMJ8$*4<#TJAAH@-1U%5G=)0J&W
MUW0>'YZX>4> #6H"^@!>\[3-@AX\-5VXEA\S?TW[P?=CTM"^TV]NGO,4O@1S
MSVVVK]BVI.O@S-5_(&@#K=?CM6EU'IV[,*WS('3B-K*9D*'$GYV=//+7G>,B
MT9DKQMQ[EH*'Z%6.[^7;9W2^#J\+H\%U]\[*(2/VCN.\?'SYS;-K)5?.WMR^
M<?N(">N_&WGEU %$XYV#BAQ.4 8O-!Z=P%_>9^C< 8-WA7&8G%?(H@?KS&'
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M"5*9@23$^WU#[MUG]]HM9K<3. [N3^?9!9H9_\/F+#_!K.?V[VU4"Y%)*:.
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M9FYJ.^S.\2.DV@(&#6%(RVONE+5-![R[?AG(*!;CX54KTH9\>V92,OX9\J[
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MI[.S\%!!'Z!4#\^I[JJ1<S]^J&?-L7QH;@"_I_I(WLRGG]R6$ _UU.TH!HQ
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M3A$HA;=-M"FP>@D<6Z9O?^''K\X[MV<_> E": $0.36@@>+]*F];RN2:@P7
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M0^H+NI]F@:-D9I.W[OS.7?EIZPNWO"<4%C&O2:,6"C&TDTWG+8PHA'+6D?W
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<VJ(MVGZD_3^O7&"O['S'5@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
